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ABSTRACT
With the completion of the fission converter epithermal neutron beam (FCB) at MIT,
which has a higher epithermal neutron flux (1.3 x 1010 neutrons/cm 2sec) than the current m-67
beam, future BNCT irradiations conducted by the Harvard-MIT BNCT program could be reduced
from approximately 3 hours per beam to just a few minutes. Therefore, it is essential to
determine the optimal time after BPA administration to deliver the neutron irradiation, thereby
maximizing the dose to tumor and minimizing the dose to the normal tissues.
The major goal of this thesis was to gain detailed knowledge of the temporal and spatial
distribution of ' 0B in normal tissues and tumors following intravenous BPA-fructose
administration, and to use a three-compartment model to study the pharmacokinetics of BPA-f in
these tissues. This entailed the investigation of the time-dependent biodistribution of BPA-f in
normal brain and in two murine tumor models, GL261 glioma and intracranial B 16 melanoma.
From the normal brain study it was shown that there were slight variations in the spatial
BPA-f biodistribution in normal brain tissues. The cerebellum and the intracranial nerves
consistently showed higher 1 B concentrations than the right cerebrum, the left cerebrum, and the
brainstem throughout the whole time course studied. This result, if verified, has important
treatment planning implications.
It was observed that for GL261 glioma tumor, both the tumor to normal brain ratio and
the tumor to blood ratio varied with time, and the best time for neutron irradiation was probably
around 60 minutes after the bolus injection. For the B16 intracranial melanoma murine model,
the neutron irradiation could be performed during the time frame between 60 and 80 minutes after
the bolus injection. The three-compartment pharmacokinetic model parameters (ki through k4)
for GL261 tumor were 0.14 ml/g/min, 0.12 min', 0.08 min-1 , and 0.036 min-', respectively, and
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for B16 tumor were 0.22 ml/g/min, 0.19 min', 0.058 min-', and 0.011 min-'. The rate constants
from the murine tumor models differed substantially from the values another investigator
(Imahori) obtained for human GBM by PET scanning, which were 0.027 ml/g/min, 0.041 min',
0.029 min-', and 0.013 min-, respectively. From these two intracranial murine tumor models it
was shown that both the tumor to blood and tumor to normal brain '4B concentration ratio
changed in time, and that the tumor BPA-f pharmacokinetics varied with tumor cell lines, thereby
affecting the optimal timing of the irradiation.
An additional experiment was conducted to investigate whether hepatic colorectal
metastasis, another tumor refractory to current treatments, could be a viable candidate for BNCT.
The experiments showed that the tumor boron was up to 2 times higher than in normal liver at 60
and 120 min after the bolus injection. Therefore, even in a highly vascularized host environment
such as the liver, there was still preferential uptake of BPA-f by tumor cells, suggesting that
colorectal liver metastases might be a suitable opportunity for BNCT.
Our results show that the animal models we have studied are associated with highly
complex BPA pharmacokinetics. This reveals practical treatment planning concerns with regard
to radiation sensitive areas such as the optic chiasm due to the higher 10B concentrations observed
in the intracranial nerves. Our results also demonstrate different BPA pharmacokinetics in
different tumor lines. Therefore, although a three-compartment model can be used to study the
pharmacokinetics, a uniform set of pharmacokinetics parameters cannot be used. Our results
further show that although the uptake ratio in hepatic colorectal metastasis might not be sufficient
for BNCT, preferential uptake is still demonstrated in a highly vascularized host environment, an
indication that other tumors might be plausible candidates for BNCT.
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Chapter 1
Introduction
1.1 Background
Boron neutron capture therapy (BNCT) is a binary radiation therapy modality that
has the potential to selectively target tumor cells[I-3]. The physical principle of BNCT
was first introduced by Gordon Locher from the Bartol Institute in Pennsylvania in
1936[4], only 4 years after the discovery of the neutron. It is based on the (n, X) nuclear
reaction that occurs when the stable isotope '0B is irradiated with thermal neutrons. The
two components of BNCT, pharmaceuticals labeled with '0B isotopes and thermal
neutrons, have very little effects on cells individually. However, when the two
components are combined, i.e. when the tissue loaded with the '0B-labeled compound is
irradiated with thermal neutrons, a reaction occurs which is lethal to the boron-containing
cell. The thermal neutron is captured by the '0B atom, forming the excited state of "B.
The "B atom then immediately disintegrates to give off an alpha particle and a recoiled
Lithium-7 ion, two high-energy heavy charged particles that cause radiation damage in
the cells in which the 10B is located.
There are several factors that make '0B containing compounds ideal for NCT
applications. First, the '0B isotope is readily available, comprising approximately 20% of
naturally occurring boron. Secondly, the 10B nucleus has a very high capture cross
section for thermal neutrons (3837 barns), so it is easy to achieve a reasonable reaction
rate with a relatively low concentration of '0B. Thirdly, the two fission products that
result from the absorption of thermal neutrons by 10B deposit their energy within - 10 pm
of the reaction origin. Therefore, if the '0B containing compounds can be selectively
concentrated in tumor cells, these cells will receive a higher radiation dose than their
normal tissue counterparts. Figure 1.1 illustrates the '0B (n, X) 7Li nuclear reactions[5].
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B + n h 4 +He+ 7Li + 2.79MeV(6%)
B + n 4 He+7Li + 0.478MeV + 2.3 1MeV(94%)
Figure 1.1. Nuclear reactions of 10B and thermal neutrons
Much of the selectivity of the radiation damage provided by BNCT depends on
the ability of the 10B containing compounds to both selectively concentrate in tumor cells
relative to surrounding normal tissues, and to have a sufficiently high absolute
concentration of 10B in tumor tissues. In the initial trials of BNCT back in the 1950s, the
1 B-labeled chemicals used did not possess this desired capability. The low selectivity of
the '0B-labeled drug and the shallow penetration depth of the thermal neutron beam used
at the time resulted in the failure to show any efficacy in the early BNCT clinical trials
that were conducted at Brookhaven National Laboratory (BNL) and at Massachusetts
General Hospital (MGH)/Massachusetts Institute of Technology (MIT)[6]. In fact, the
high boron concentrations in blood during irradiation resulted in damage to the normal
brain vasculatures. The clinical trials in the United States were therefore terminated.
Clinical work continues in Japan beginning in 1968 and for decades, the only clinical
BNCT experimentation was conducted by Dr. Hatanaka[7], and later by Dr.
Nakagawa[8]. With the development of 10B labeled compounds with more selective
tumor uptake, such as sulfhydryl-containing polyhedral borane (BSH) and
boronophenylalanine (BPA), and the design of more penetrating epithermal neutron
beams, clinical trials are once again being conducted in the United States, both at MIT
(the Harvard-MIT BNCT Program)[9] and at BNL[1O]. In Europe, an EORTC phase I
clinical trial is currently underway in Petten, The Netherlands[ 11 ]. There are other
European groups in Finland[12], Sweden and the Czech Republic that are preparing to
start BNCT clinical trials in the near future.
The 'B-labeled compounds BSH and BPA currently used in clinical trials have
both been evaluated in a range of normal tissues and tumor types both in human
biodistribution studies and in animal models. Their tissue distribution patterns and
radiobiological characteristics are summarized in the recent review by Coderre and
Morris[13]. BPA-f, a L-p-boronophenylalanine-fructose complex that is more soluble
than the L-p-boronophenylalanine alone[14], was chosen for use in the U.S. clinical trials
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because of its superior in vivo tumor targeting ability and proven effectiveness in the
treatment of experimental brain tumors in rats[14-17] and in mouse[18, 19]. Advances
have also been achieved in neutron beam technology. The beams currently used in
clinical trials are epithermal neutron beams, which have much better penetration depth
into tissue as compared to the thermal beams used in the earlier clinical trials, thus
making the treatment of deep-seated tumors possible. The most recent advance in
neutron beam design by the Harvard-MIT BNCT Group is the high-intensity, high-
quality Fission Converter Beam (FCB)[20].
The total BNCT radiation dose in tissue is composed of several dose components:
the high LET fission products of the 'B(n, )?Li reaction; the 490 KeV protons released
from the 14N(n,p) 14 C reaction produced by the nitrogen in tissue; the recoil protons
produced from the 'H(n,n')p reaction in tissue; the structural incident gamma rays
(y) inherent in the neutron beam; and the induced y from the 'H(n, y) 2H reactions. The
FCB, at a reactor power of 5 MW, will have epithermal flux in excess of 1010 n/cm 2-s
with negligible photon and fast neutron contamination, i.e., <2 x 10-" cGy-cm 2/n[20].
With the lower contamination and the higher epithermal neutron, a greater proportion of
BNCT dose will come from the 'B(n, c)?Li reaction dose component, while reducing the
treatment time to a few minutes. A thorough understanding and characterization of the
pharmacokinetics of BPA in tumor and normal tissues will make more accurate treatment
planning possible, and fulfill the optimal use of the FCB neutron source. It was toward
that end that this research was initiated.
1.2 Research Goals
The present focus of BNCT research is the treatment of brain tumors, primarily
glioblastoma multiforme, and the goal of the Phase I clinical trial is to find the maximum
tolerance dose to the normal CNS. The physical dose contributed to the CNS by '0B
during BNCT is a function of both the neutron fluence and the 10B concentration in the
parenchymal tissue and the blood. The dose contribution is calculated based on the 10B
concentration in blood samples taken after BPA infusion because it is not practical to
measure 10B concentration in CNS tissue during the irradiation. The 10B concentration in
13
tumor tissues is obtained by multiplying the blood 10B concentration by a factor obtained
through animal studies and human biodistribution studies[21]. The ratios of 10B
concentrations currently used by the Harvard-MIT BNCT program for tumor/normal
brain and for normal brain/blood are 3.5 and 1, respectively.
With the completion of the fission converter epithermal neutron beam (FCB) at
MIT, which will have a higher epithermal neutron fluence (1.3 x 1010 neutronsc/cm 2sec),
future BNCT irradiations conducted by the Harvard-MIT BNCT program could be
reduced from approximately 3 hours per beam to just a few minutes[20]. As mentioned
above, the new beam also will have negligible fast neutron and structural gamma
components, making the '0B dose component more prominent, and thus more tumor
selective, in the overall dose delivered. An optimal therapeutic gain is expected when
patients are irradiated during a time window which has the best tumor/normal tissue ' 0B
concentration ratio, and when the 10B concentration is high in the tumor.
With the current M67 beam and long irradiation time, variations in the
tumor/normal tissue '0B concentration ratio throughout the entire irradiation time course
would be averaged out, minimizing any dosimetric impact such changes might have.
However, with the reduction in unwanted dose components in the FCB and its capability
to deliver BNCT in a few minutes, it is important to determine the biodistribution and
pharmacokinetics of '0B in both the normal brain and tumor tissues. Not only will this
knowledge lead to more accurate dosimetric calculations, it will also be possible to
determine the optimal time after BPA administration to deliver the neutron irradiation,
thereby maximizing the dose to tumor and minimizing the dose to the normal tissues.
In phase I clinical trials in which the treatment target is the brain, in addition to
the surrounding CNS tissue, other structures in the head such as the eyes and the optic
tract are also of interest when studying toxicity. The biochemical rationale for the
preferential uptake of BPA in tumor is thought to be an elevated rate of amino acid
transport at the tumor cell membrane[22, 23]. It has been noted in the literature that there
are differences in phenylalanine influx in different brain structures[24], with globus
pallidus (basal ganglion) being the lowest and inferior colliculus (center for auditory
reflex) being the highest. Although BPA is structurally closer to tyrosine, another large
neutral amino acid, BPA is a derivative of phenylalanine. Therefore, it is conceivable
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that BPA influx, and BPA concentration, might also differ in different brain structures.
Knowledge of the spatial biodistribution of BPA-f in the normal brain tissues and
structures such as the optic nerve is essential to be able to prescribe accurate radiation
dose to radiation sensitive areas such as the optic chiasm.
This thesis research was initiated in order to gain more detailed knowledge of the
temporal and spatial pharmacokinetics of '0B in normal brain tissues and tumors
following intravenous BPA-f administration. In the Phase I clinical trial conducted by
the Harvard-MIT BNCT program, two tumor types, glioblastoma multiforme and
intracranial metastatic melanoma, are currently under study. To gain insight into the
pharmacokinetics of these two types of tumors, two comparable murine tumor models,
GL261 glioma tumor and B16 melanoma tumor, were utilized in this research to study
the time-dependent biodistribution of BPA-f.
The success of boron neutron capture therapy depends on its applicability to
tumor types that cannot be treated successfully by conventional radiation therapy. It is
possible that other types of tumors are better candidates for BNCT than the two currently
under investigation. Attempts have been initiated to find other plausible candidates for
BNCT. As part of that effort, in this thesis research an experiment was conducted to
investigate whether hepatic colorectal metastasis, another tumor refractory to current
treatments, could be a viable candidate, and determine whether the same favorable tumor
to normal tissue ratios were seen in a different system.
It is hoped that detailed knowledge of the phamacokinetics of BPA-f could be
used in future work to develop a mathematical model to describe the complex
relationship between blood, tumor and normal tissue. Future research could be carried
out to manipulate BPA transport through the blood-brain barrier and study ensuing
changes in pharmacokinetic parameters. This, in conjunction with the blood
pharmacokinetic model developed by Kiger[25], could lead to the development of
treatment plans that incorporate the most advantageous BPA-f infusion schedule and time
for neutron irradiation.
Chapter 2 presents the analytical tools used in this research, namely, the two
techniques employed for measuring ' 0B concentration, and the 3-compartment model
used to evaluate the pharmacokinetic parameters. Chapter 3 describes the four sets of
15
animal experiments conducted, and discusses the results obtained and their significance
and implications. The final chapter summarizes the results of this thesis, and
recommends ideas for future work.
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Chapter 2
Analytical Tools
This chapter presents the analytical tools used in this thesis. The first section
describes the 10B quantification methods employed to obtain the 10B concentration data.
The B concentrations are measured by two methods, prompt gamma neutron activation
analysis (PGNAA) and Induction Coupled Plasma-Atomic Emission Spectroscopy (ICP-
AES). An intercomparison between the '0B concentrations measured by the two methods
is presented. The second section shows the compartment model used to study the BPA
pharmacokinetics.
2.1 "Boron Quantification
2.1.1 Introduction
10B quantification is vital for BNCT treatment planning and dosimetry
calculations because the dose delivered is largely dependent on the 10B concentration in
normal tissue and tumor. Macroscopically, 10B quantification can be performed using
Prompt Gamma Neutron Activation Analysis (PGNAA)[1], Inductive Coupled Plasma-
Atomic Emission Spectroscopy (ICP-AES), Directly Coupled Plasma-Atomic Emission
Spectroscopy (DCP-AES)[2], or Electrothermal Atomic Absorption Spectrometry[3].
Microscopically, 10B quantification can be achieved using ion microscopy[4], and alpha
track etching technique, such as the High Resolution Quantitative Autoradiography
(HRQAR)[5, 6] developed by the Harvard-MIT BNCT group.
The exact intracellular spatial location of 10B can strongly influence the biological
effect of the high energy heavy particles produced following the 10B (n, X) 7Li reaction;
therefore, microscopic quantification of 10B is important for microdosimetric analysis.
However, macroscopic measurements are simpler and faster than microscopic techniques.
For the determination of 10B concentration in blood and tissue, macroscopic
measurements give sufficient data to determine the pharmacokinetics of BPA-f in various
tissues as desired. This research used prompt gamma neutron activation analysis
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(PGNAA) for blood '0B measurements, and used Induction Coupled Plasma-Atomic
Emission Spectroscopy (ICP-AES) to quantify tissue 10B concentrations.
2.1.2 PGNAA Method
At the Harvard-MIT BNCT Group, boron analysis of the blood is usually
performed macroscopically using Prompt Gamma Neutron Activation Analysis
(PGNAA). This is the method of choice for the blood 10B quantification for this thesis
research. The PGNAA method is a nondestructive nuclear analytical technique that
detects the 478 keV photons produced from the de-excitation of the lithium recoil nucleus
resulting from the 10B(n, X)7Li reaction. The number of counts integrated in the 478 keV
peak is proportional to the number of boron atoms present in the sample. Figure 2.1
shows a schematic of the decay mechanism for the excited state of 11B[7].
11B*
0.478 MeV
T1/2 -
10-13S
2.31 MeV
93%
2.79
60/
MeV
y
Figure 2.1 Decay Scheme of "B*
At the MITR-II 5 MW research reactor, the PGNAA facility is currently situated
on the 4DH3 beam port and was redesigned and reconstructed by Kent Riley in 1997[8].
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This led to an increase of the flux at the sample position by a factor of three (to 1.7 x 107
n/cm 2 ), an increase in sensitivity by a factor of 2.5, and a decrease in the background seen
by the High Purity Germanium (HPGE) crystal[8]. The boron sensitivity is 18.6 cps/tg
at the MIT-II PGNAA system, and its limit of detection is 0.25 jig[9].
For the measurement of blood samples, the samples are pipetted into cylindrical
Teflon vials that are 1.5 cm high and 1.3 cm in diameter[8], and are placed manually one
by one into the 4DH3 beam port of the MITR-II Research Reactor. Teflon vials are used
because they will not be activated by the neutrons. The measurements usually proceed
until less than 5% error in 10B counts is obtained; most of the higher concentration
samples have less than 3% error. For a 0.5 ml sample with a 10B concentration in the 2-4
ppm range, it typically takes 20 minutes or more to reach a 5% error in 10B counts. For a
0.5 ml sample with 30 ppm 10B concentration, counting the sample for 1 minute will
usually yield less than 2% error. System calibration is performed on each day of
measurement using natural boric acid obtained from the U.S. National Institute of
Standards and Technology (NIST). The standards used for the construction of the
calibration curve should have the same volume as the samples to reduce the artifacts
introduced by different volume and geometry. A background hydrogen count rate and a
1B background count rate (blank standard) check is also performed for each reactor
startup period if the reactor has been shut down in the days prior to the measurements.
The background H count rate is measured by placing an empty Teflon vial into the beam.
To measure the background 10B count rate, deionized water of the same volume as the
sample is placed in the sample position. Deionized water is used for the blank standard
because its hydrogen content is similar to that of blood and tissues, about 11%. To
control for possible flux variation during measurements and inhomogeneity in the sample
composition and geometry, the B/H ratio method is used to calculate the 10B
concentrations. The sample 10B concentration is obtained by comparing the B/H ratio in
the sample with the B/H ratio vs. 10B concentration calibration curve.
2.1.3 ICP-AES Method
Inductive Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES) is an
atomic excitation technique. It is insensitive to different isotopes of the same element
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and is a destructive analysis technique. The principle of ICP is as follows: 1) Argon gas
flows through a torch, the end of which is surrounded by a RF coil that sets up an
oscillating electromagnetic field. 2) Argon ions are generated when the torch is ignited.
These charged ions are caught up by the oscillating electromagnetic field and try to
follow the direction of the field. 3) This causes the ions to oscillate rapidly, striking more
argon atoms in the process, which in turn become ionized, generating secondary ion pairs
of argon ions and electrons. 4) The number of ions rapidly increases until a steady state
is reached, and a plasma is formed. 5) A peristaltic pump ensures a steady sample flow
rate and introduces the samples into a cross-flow nebulizer. 6) The nebulizer vaporizes
the liquid samples, and injects sample aerosols into the argon plasma. 7) When the
sample atoms are introduced into the plasma, they collide with the rapidly moving argon
ions and become themselves excited. 8) The excited sample atoms and ions pass through
the plasma, relax to lower energy states, and emit characteristic photons. 9) A
spectrometer measures the intensity of the characteristic de-excitation photons from all
isotopes of boron. The number of detected photons is proportional to the amount of
boron present in the sample.
To use the ICP-AES to measure tissue 10B concentration, the tissue samples must
first be acid-digested. The procedures are the same as sample preparation for DCP-AES,
and are summarized as follows[10]. The tissue samples are weighed; for every 50 mg of
tissue, 0.15 ml of nitric acid:sulfuric acid (1:1) mixture is added; digestion is allowed to
proceed for an hour in a 60'C shaking waterbath. 0.5 ml of 2.5% Triton X-100 is then
added to the acid-digestate, which is then placed in the 60'C shaking waterbath for
another hour to complete the digestion process. Finally, the acid-digested solution is
diluted to a final volume of 1 ml by adding DI water[10]. The solutions are filtered using
0.22 gm filters and their B concentrations measured using ICP-AES. Typically 0.1 ml of
sample solution could be lost during the filtration process, and would be accounted for
during sample concentration calculations. Since AES techniques rely on atomic
emission, the chemical environment of the sample atoms will affect the number of atoms
being excited. As a result, different chemical environments between the standards and
the samples would cause artifacts in the calibrations. To minimize this kind of matrix
effects, standards are prepared in a similar manner using natural boric acid obtained from
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the U.S. National Institute of Standards and Technology. Since the standards are
prepared using boric acid and the animals are injected with BPA-f, an additional standard
using a known concentration of BPA-f is also included to study the possible matrix
effects. Although the effects of the acids, the Triton X-100, and BPA-f are taken into
account by preparing the standards the same way as the samples, since there is still
difference between tissue samples and boric acid standards, this artifact could not be
avoided totally
The boron standards for the ICP-AES are also analyzed with the PGNAA system
to provide system cross-calibration. System calibration is performed on each day of
measurement. For measurement times longer than 2 hours, the temperature in the ICP-
AES machine rises, causing the machine monochromater calibration to drift. Therefore,
the monochromater is reprofiled every 2 hours, and a new system calibration is
conducted. The ICP-AES machine used for this research (Spectroflame ICP-D) has a B
sensitivity of about 2500 cps/gg, and thus can be used to measure low B concentration or
small tissue samples[9].
The calibration curve obtained gives the solution B concentrations in gg B per ml
of solution. To obtain the actual B concentration in terms of gg B per gram of tissue, the
solution B concentration is multiplied by the total solution volume (before filtration).
The total amount of B is then divided by the weight of the tissue, thus giving the B
concentration in gg/g.
2.1.4 Error Analysis
10B concentrations obtained by PGNAA and ICP-AES are measured by
comparing the sample count rates to that of the standard calibration curve. Therefore, in
addition to the inherent statistical uncertainties, the uncertainty in the calibration curve
also needs to be taken into account. In this section, a brief summary of the error
analysis[7] for these measurements is presented. The following equations show the error
analysis for PGNAA measurements; the error analysis for the solution concentration
obtained by ICP-AES is similar, with an additional error propagation step for the
uncertainties in the tissue weights, and will not be described. The nomenclature used
are as follows: Area = area under the peak of interest
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NCR = Net Count Rate,
BCR = Background Count Rate
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For ICP-AES measurements, the count rates measured can be directly substituted
in place of the B/H ratio. As mentioned before, the use of the B/H ratio is to avoid the
error that might arise if the sample has inhomogeneity in its composition or geometry,
and is not applicable to the ICP-AES measurements.
Most of the PGNAA sample measurements are measured for long periods of time
until the 10B peak area errors are less than 3%, and the H peak errors are less than 1%.
We have chosen long measuring times such that after proper error propagation is carried
out to account for the uncertainty in the calibration curve, the percent error in the 10 B
concentrations calculated would be between 5% and 7%.
2.1.5 Intercomparisons of PGNAA and ICP-AES measurements of 10B
concentrations in murine lungs
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Experiments were conducted to ascertain that the 10B quantification methods used
in this thesis produce accurate and repeatable results, and that the measurements obtained
by PGNAA and ICP-AES could be used together in a study.
An experiment was designed and conducted to study the repeatability of PGNAA
measurements. Table 2.1 shows the results of that experiment. Not only are PGNAA
measurements quite repeatable if the liquid sample is left undisturbed, even if the sample
vial is taken out of the sample holder and then replaced, the results are still quite
repeatable. Therefore, it seems that PGNAA measurements are quite repeatable if the
sample is in liquid form with no geometric and composition inhomogeneity.
Table 2.1 PGNAA repeatability test
Another experiment was conducted using PGNAA to measure tissue samples.
One lung sample was measured 5 different times, with the sample being placed in
different parts of the Telfon vial. In one position, the sample was spread out at the
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Sample # 10B concentrations (ppm)
Blood 17 12.3± 1.0
Without movement 11.5 ± 0.9
Without movement 12.5 ± 0.9
Without movement 12.0 ± 1.0
Without movement 11.7 ± 0.8
Without movement (Avg) 12.0 ± 1.6
Blood 17 12.1 ±0.8
Taken out then replaced 12.4 ± 0.9
Taken out then replaced 12.4 ± 1.0
Taken out then replaced 12.5 ± 0.9
Taken out then replaced 12.3 ± 0.9
Taken out then replaced (Avg) 12.3 ± 1.5
bottom of the vial, while in the other positions, the sample was placed to one side of the
vial, and rotated 90' for each measurement. Two pieces of 30 ppm chicken liver
HRQAR standards were also included as monitor checks. The results are presented in
Table 2.2.
B-10 B-10 % difference % difference
Sample Weight Conc. Conc.B between B/H from known
(mg) B/H Ratio peak alone and B alone conc.
lung #11
(flat on 48.3 29.8 ±2.6 31.4 ±2.6 5.1 % N/A
bottom )
lung #11
(left side) 30.1 ± 2.2 28.4 ± 2.3 -6.0 % N/A
ung #11
(front side) 27.4 ± 2.2 28.1 ± 2.4 2.5 % N/A
ung #11
(right side) 26.5 ±2.3 34.4 ±3.0 23% N/A
lung #11
(rear side) 26.1 ±2.1 37.2 ±3.2 30% N/A
30 ppm 6 % (B/H)
chicken 48.5 28.2 ± 2.6 26.7 ± 2.2 -5.6 % 11 % (B)
liver
30 ppm -15 % (B/H)
chicken 44.1 34.4 ± 3.0 22.6 ± 1.9 -52 % 25 % (B)
liver
lung #15
(flat on 52.4 23.2 ± 1.9 29.5 ± 2.4 21% N/A
bottom)
lung #32
(flat on 37.9 19.4 ± 1.5 18.3 ± 1.5 -6.0 % N/A
bottom)
lung #31
(flat on 47.4 19.5 ± 1.7 19.3 ± 1.6 -1.0 % N/A
bottom) I I I I I _I
Table 2.2 PGNAA measurements of lung tissues and chicken liver standards.
Background B-10 count rate for 0.05 ml of DI water was 10.55 cps.
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From Table 2.2, it is clear that there is variation between the 10B concentrations
obtained when small tissue samples were placed in different parts of the vial. However,
this difference is only around 20%, and is probably due to the spatial difference in the
neutron flux and detector efficiency. Also, PGNAA measurements of the 30ppm chicken
liver standard used in HRQAR experiments showed a 15% difference from the known
concentration. Therefore, compared with the high repeatability observed in liquid
samples, it appears that PGNAA may not be the best technique to use when measuring
small tissue samples if high accuracy is required.
An intercomparison experiment between PGNAA and ICP-AES was designed
and carried out. Lungs from 4 healthy mice were removed at different time points after
350 mg BPA-f/kg body weight bolus injection. The lung samples were first measured by
PGNAA, and then were acid-digested and measured by ICP-AES. BPA-f samples were
measured at the same time to serve as a monitoring check. Table 2.3 shows the results of
this comparison experiment.
mouse # Time after BPA PGNAA ICP-AES % Difference
Injection (min) (ppm) (ppm)
51 119 4.5± 0.4 6.1 ±0.3 26 %
42 240 1.5± 0.2 2.8 ±0.2 44 %
41 6 21.1 ±1.7 17.8 ±0.7 -19%
50 28 10.9 ± 0.8 12.7 ± 0.5 14 %
BPA-f (100x) 14.4 ±1.0 14.7 ±0.5 1.8%
Table 2.3 PGNAA and ICP-AES 10B measurement comparisons
From Table 2.3, it is clear that for the liquid sample (BPA-f), the difference
between PGNAA and ICP-AES 10B measurements is very small, only 1.8%. However,
for tissue samples, the difference becomes greater. The difference between PGNAA and
ICP-AES I0 B measurements is between 14 - 26%; as seen in the experiment mentioned
above, this difference is within the PGNAA measurement variations detected for small
tissue samples. The only significant difference between the two measurements is sample
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#42, with a difference of 44.55%. This sample was collected 240 minutes after injection,
when the blood 10B concentration is typically around 2 ppm. Therefore, with a low 10B
concentration and small tissue size, this sample might have reached the lower limit of
PGNAA detection limit for the time it was measured (~30 minutes). A longer measuring
time might have yielded better agreement.
From these intercomparison data and the PGNAA repeatibilty tests, a few
conclusions can be drawn. If the sample is of liquid form, the PGNAA and ICP-AES
measurements are within a couple percent of each other. If the samples are tissues and
they are small, there seems to be a difference of 14% to 26%. However, for small tissue
samples, PGNAA measurements vary depending on the location of the tissues placed in
the Teflon vials, and this variation is itself around 20%. Therefore, for small tissues, it
appears that ICP-AES would be a better technique to use to quantify the boron
concentration. In conclusion, the two techniques give accurate boron measurements, and
that the 10B concentrations measured by the two techniques can be used in conjunction to
study the pharmacokinetics of BPA-f.
2.2 Pharmacokinetic Modeling
2.2.1 Introduction and background
In a general sense, pharmacokinetics is the study of the kinetics of absorption,
distribution, metabolism, and excretion of drugs and their pharmacological, therapeutic,
or toxic effects in animals and human[ 11]. Each drug has its own site of action, and a
characteristic profile of distribution. After a drug is introduced into a biological system,
the concentration of the drug at the site of action depends on several factors that may
influence drug distributions to different tissues. They are: 1) plasma protein binding; 2)
specific receptor sites in tissues; 3) regional blood flow; 4) lipid solubility; 5) active
transport; 6) disease; 7) effect of other drug[12]. Many drugs are bound to circulating
proteins, such as albumin, globulins, lipoproteins, and acid glycoprotein[12]; only the
fraction of drug that is non-protein-bound can bind to cellular receptors and be
transported in and metabolized at the site of action. For most drugs, however, the extent
of protein binding is not large, and this fact therefore has little effect on drug distribution.
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If the site of action is a well-perfused organ, such as the heart, kidneys, or liver, they
usually will accumulate a higher concentration of the drug than that fat or bone, which
are poorly perfused. Since cell membranes are formed by lipoproteins, if the drug is non-
polar, and therefore relatively lipid-soluble, it will distribute more readily to tissue than a
polar drug. A drug will accumulate preferentially in its site of action if there are specific
receptors or carriers to actively transport the drug into the cells. Lastly, diseases can
affect the distribution characteristics of a drug. For example, renal failure will increase
the plasma concentration of a drug.
The important kinetic processes which affect the concentration of drug at the site
of action are those that govern the entry of the drug into the blood, its distribution in body
tissues, and its elimination from the blood by metabolism and excretion. These processes
are generally "zero-order" or "first-order". Zero-order kinetics describes a drug is which
the metabolism rate is independent of the amount of drug administered. When the
concentration of a drug approaches a value at which its metabolizing enzymes are
saturated, its rate of metabolism becomes predominantly zero-order. Most kinetic
processes affecting drug disposition are first-order[12]. A first-order process is one
whose rate is directly proportional to the amount of drug undergoing the process. A good
example is drug plasma concentration versus time. When a bolus intravenous injection is
administered, the plasma concentration at first falls rapidly, but decreases more slowly
later. The rate of decrease at any time is proportional to the concentration at that time.
There are several parameters that are widely used in drug pharmacokinetics.
They are 1) biological half-life; 2) apparent volume of distribution; 3) clearance[12]. For
zero-order processes, the half-life is dependent on the initial concentration; the larger the
initial concentration, the longer the half-life. For first-order processes, the half-life, the
time required for half of the drug to disappear, is constant. The apparent volume of
distribution of a drug, Vd, may be hypothetically defined as the volume of body water
required to contain the amount of drug in the body if it were uniformly present in the
same concentration as in the blood. It is written as
D, = VJ
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where Dt is the total amount of drug in the body, and Pt is the concentration of drug in the
plasma. Clearance, C, is an expression of the loss of drug from the body. It is related to
the half-life and the apparent volume of distribution by the following equation,
0.693V
tl
t 2
The kidney is the primary route for the excretion of drugs, therefore, it is important to
determine the renal clearance, CR. This is defined as the volume of plasma (in ml) that is
cleared of a substance by the kidneys in 1 minute[12].
These parameters are useful indicators of drug pharmacokinetics. However, due
to the fact that the concentration of the drug at the site of action is often unknown, to
determine an accurate dosage regimen, it is important to employ compartment modeling
to predict the concentration at the site of action.
2.2.2 History of Compartment Modeling in Biological Systems
The origin of compartmental analysis can be traced back to tracer studies done in
the early 1920s. In order for a tracer studies to accomplish it goal of studying the
dynamic behavior of a certain substance, the biological system should not be able to
distinguish between the natural substance and its tracer. Tracers are usually added in
small amounts so they will not disturb the steady state existing in the system as a whole.
The first tracer study was done using radioactive isotopes as tracers, Hevesey used
radioactive lead to demonstrate the uptake and loss of lead by the roots of Viciafaba[13].
As other isotopes became available, many organic compounds were synthesized to
qualitatively study the metabolic processes of lipids and proteins in animal models. From
these studies, it was concluded that lipids and proteins were constantly being degraded
and resynthesized. Although theoretical treatments for drug kinetics have existed since
1920[13], the first adequate quantitative treatment of these tracer studies was the classical
paper by Zilversmit, Entenman, and Fishler[14]. Starting in the late 1940s, the concept of
compartments and the use of differential equations to describe the behaviors of tracers
became increasingly important as more research was conducted to study the dynamic
behaviors of biological systems.
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2.2.3 A two-compartment closed system analysis of tracer study
For compartment analysis, a one compartment model is the most simple to study.
It represents uptake from a constant source, or elimination of drug from the body by all
routes. Since the calculation is easy, it won't be discussed here. The transport of drug
can either be passive diffusion or active transport. Passive diffusion can be represented
by a closed two-compartment model[1 1]. In pharmacokinetics, it is the amount of drug
transferred across a membrane and the rate of transfer that are of interest. The rate
constants can be determined from the amount of drug in each compartment. Figure 2.2
shows a system consisting of 2 compartments separated by a permeable membrane. An
example of such a system is the exchange of tritium-labeled water between plasma and
ascitic fluid[ 11]. The radioactive tracer initially introduced into compartment A is
represented as R. The amount of the unlabeled substance in compartment A is denoted as
QA, and the amount of unlabeled substance in compartment B is QB. The amount of the
tracer in compartment A is represented by qA, its specific activity aA(counts/min/mg); and
the amount of tracer in compartment B is qB, and its specific activity is
aB(counts/min/mg). The first-order forward rate constant is ki(min-1 ), and the first-order
reverse rate constant is k2(min 1). The equations describing the transport process are
shown below.
Compartment k - Compartment
A -- B
k2
Permeable
membrane
Figure 2.2 2-compartment model
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R Compartment k - Compartment
A 4--- B
_ _ _ _ _ - k2
Permeable
membrane
Figure 2.2 2-compartment model
The differential equations for the unlabeled substanc in steady state are
-dQA = klQA 
- k2QB =0
dt
dQ klQA-k 2 QB=
dt
The equations for the tracer are
-dqA 
=kIq 
-k 2 qBdt
dqB = 1 q-A k 2 qBdt
Since the specific activity of a tracer equals the product of the counting efficiency
(E) and the abundance ratio, and the abundance ratio is the ratio of the amount of tracer in
the compartment and the amount of the unlabeled substance in the compartment[13], the
specific activity is
a=EqQ
For all determinations of specific activity within an experiment, E is a constant,
and could be divided out. Therefore, the rate of change of the amount of tracer is
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dq da
=- -Q
dt dt
Substituting this into equations above,
da A = k 2 aB-kaA
dt QA
daB= k1a A 
-k 2aBdt QB
By using the method of differential operators, the equations can be transformed
into algebraic equations.
Dy -dy-y'(t)
dt
DaA= k 2aB QBk AQA
DaB =k QA -k 2aB
QB
By rearranging the variables, these two equations become
aA(D+k) a~k2  0
QB
a kQ aB(D+k 2 =O
QB
These two equations can be manipulated algebraically,
aB[D+(k 2 +k3)]D=0
a[D+(k 2 +k 1)]D=0
and the solutions are
aA =m1+m 2 e k2+k1)t
aB= n 3 + m 4 e-(k2 +kl)t
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Since the tracer was introduced into compartment A as R at time 0, the initial
specific activity for compartment A is aA= aA(O), and aB 0. From these initial
conditions, the m's are
n 2 - kaA(0)(k2 + k1)
n1 - k2aA(0)(k2 + k)
_ klaA(O)QA
(k2 + k)QB
SklaA (O)QA
4 (k2 +k )QB
Therefore, the solutions to the original differential equations are
a A = aA () [k ke (k2+kl~(k2 + k1)[2 1 it
a kaA(O)QA [1e -(k 2 +k1)t
(k2 +kl)QB
It is then possible to obtain the values of the parameters using minimization of the sum of
squares.
2.2.4 Three-Compartment Modeling
In most compartmental analyses, the compartments are assumed to be
homogeneous. If there is a non-homogeneous compartment, it is commonly represented
by 2 homogeneous subcompartments. One of the subcompartments can exchange rapidly
with the rest of the system, while the second subcompartment exchanges slowly with the
first[13]. The system is then represented by a 3-compartment model. This type of model
is best applicable for the BPA-f pharmacokinetics. The extracellular and intracellular 10B
concentrations are different in the brain; therefore, the brain cannot be treated as a
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homogeneous compartment. However, there is currently no knowledge of the exact
metabolism of BPA-f after administration. Since all of the quantification techniques
measure the amount of B, the important question becomes whether 10B atoms stay bound
to the phenylalanine molecule after BPA-f has entered the body. Assuming that the 10B
atoms do stay bound, Imahori investigated BPA pharmacokinetics in patients with glioma
by using 18F-labeled BPA in a PET study. He employed a 3-compartment model to
explain the PET data[15]. Figure 2.3 shows the compartment model used for 18F-BPA-f
pharmacokinetics.
18FBPA k1 extra- k3 intra-
in cellular cellular
+--- 18FBPA 18FclA
plasma k2 k4 '8FBPA
BBB
Figure 2.3 Diagram of 3-comparment model for 1 8F-BPA-f pharmacokinetics[15]
The 3-compartment model is used in chapter 3 to determine the rate constants for
GL261 and B 16 intracranial tumors in mice; its kinetics are shown below. In the model
shown in Fig. 2.3, the rates of change of the intracellular and extracellular '8 FBPA-f
concentrations in tissue (Ce and Cb) are equal to the net transport of '8 F-BPA-f into the
respective compartments.
d
-- C =kC, -(k 2 +k3 )C + k4C (1)dt
d
-- Cb = k3Ce - kGCb (2)
dt
The extracellular '8FBPA-f concentration (Ce) and the intracellular 18FBPA-f
concentration (Cb) can be solved in terms of the BPA-f concentration in plasma (Cp) by
taking the Laplace transform of equations (1) and (2),
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SC(S) = k1C,(S) - (k2 + k3)Ce(S)+k Cb (S) (3)
(4)SCb(S)= k3Ce(S) - k4Cb(S)
where initial conditions are assumed to be zero, and Ce(S), Cb(S), and Cp(S) are the
Laplace transforms of Ce, Cb, and Cp.
C(S)= k3 Ce(S)(S+k 4 )
(5)
By substituting equation (5) into equation (3), and after some manipulation, Ce(S) can be
expressed totally in terms of Cp(S) as
Ce(S)= rk, k4 -a
a 2 - 1 S+a
a+ 
-k4 C,(S)
S+a2 )
(6)
where
(k2
a1
+ k3 +k 4-(k 2 +k3 +k 4)2 -4k2k4
(7)
+k 3 +k 4 + (k2 +k 3 +k 4) 2
After substituting equation (6) back to equation (5), Cb(S) can then be expressed totally in
terms of Cp(S) as
Cb(S)= -a 1 3 1 -
a2 -a1 S + al
1
+jCP(S)S + a2)i
By performing inverse Laplace transforms on equations (6) and (9), we
and Cb(t) in terms of the rate constants and Cp(t)
Ce(t)= k, .((k4 -
a 2 -a 1
Cb(t) - k1k3  (e-ait
2a2
a)e 
-"' + (a 2 - k4 )e-a2 ' ) 0 C,(t)
_ -a2t)0 CP(t)
can obtain Ce(t)
(10)
(11)
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C2
a2 -
4k2k4
(8)
(9)
The total amount of 10B in tissues can be denoted as Ci(t), and it is equal to the sum of
both the extracellular and intracellular BPA-f concentrations in tissues. That is
C, = C, + Cb (12)
Substituting equations (10) and (11) into equation (12), we obtain
C1(t)= 1  ((k3 + k4 - al)e-at (13)
a 2 - a1
+(a2- k3- k)e-a2 ) & C(t )
The results derived here produce the same set of equations used in the human PET
studies. For the GL261 and B16 murine tumor experiments, the 10B concentration in
tissues (C1) was measured by ICP-AES, and the blood '0 B concentration (Cp) was
measured using PGNAA. The 3-compartment model was then used to determine the rate
constants in GL261 and B16 murine tumors. The values of the rate constants were
estimated from equation (13) by nonlinear least square regression method, and they are
presented in the results section in chapter 3.
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Chapter 3
Pharmacokinetics of BPA-f in Murine Normal Brain and
Tumor Models
As stated in the introduction, with the completion of the fission converter
epithermal neutron beam (FCB) at MIT, future BNCT irradiations conducted at MIT
could be reduced to only a few minutes[1]. To obtain the optimal therapeutic gain, the
patients should be irradiated during a time window which has the best tumor/normal
tissue 10B concentration ratio, and when the 10B concentration is high in the tumor.
Therefore, a detailed knowledge of the tumor/normal tissue 10B concentration ratio as a
function of time is essential. The goal of this thesis research was to determine the
biodistribution and pharmacokinetics of 10B in both normal tissues and in tumor tissues.
Four separate experiments are presented in this chapter. The first section
describes and discusses the spatial BPA-f biodistribution in normal brain tissues for both
250 mg/kg and 350 mg/kg BPA-f administrations. The second experiment deals with the
pharmacokinetics of BPA-f in intracranial GL261 murine glioma tumor model. The
results are discussed and the data are fitted to a 3-compartment pharmacokinetic model.
The third experiment shows the pharmacokinetics and modeling of BPA-f in intracranial
B16 murine melanoma tumor model. The final experiment presents the BPA-f
biodistribution in hepatic colorectal metastasis in nude mice.
3.1 BPA-f Pharmacokinetics Study in Normal Murine Brain Tissues
3.1.1 Introduction
The present focus of BNCT research is the treatment of a type of brain tumor,
primarily Glioblastoma Multiforme; the Harvard-MIT BNCT Phase I protocol also
includes intracranial melanoma. The normal surrounding tissue under study for the
effects of BNCT radiation is the central nervous system (CNS), and the goal of the Phase
I clinical trial is to find the maximum tolerance dose to the CNS. Animal studies have
been conducted using the rat spinal cord model to quantify the biological effectiveness of
BNCT in the normal CNS, both for BPA[2-4] and BSH[2, 5, 6]. BNCT brain tolerance
has also been studied in dogs[7-9]. From these studies, the RBEs and CBE factors of the
different dose components of BNCT were determined. However, these studies did not
address the issue of whether there is any spatial differential uptake of the 10B compounds
in various brain structures. Therefore, the brain is currently treated as a homogeneous
tissue with a uniform B concentration during treatment planning. However, the brain
consists of many different structures, each with specific cognitive and motor functions; it
is conceivable that there are differences in vascularity and metabolism in these structures.
These variations could result in different 10B pharmacokinetics in the various brain
structures. In fact, some reports on amino acid transport shows that there are indeed
differences in amino acid (tyrosine and phenylalanine) uptake in different brain
structures[10, 11], and that the different vascularity in parts of the CNS is associated with
different levels of phenylalanine influx[l1]. To accurately prescribe dose and avoid
harmful radiation damage to tissues that are radiation sensitive or have higher 10B
concentration, it is essential to determine whether there is a difference in the 10 B
pharmacokinetics in different parts of the brain. The first series of experiments were
designed to test this hypothesis, i.e., to investigate whether there is differential BPA-f
uptake in different structures of the brain, such as the right and left cerebrum, the
cerebellum, the brainstem and the intracranial nerves. Although not on the same scale as
radio-labeled amino acid and autoradiography of the brain sections[l0], this preliminary
experiment may provide information that can be used to design experiments to provide
better spatial resolution. The section that follows presents the methodology of the
experiments and results of both the spatial and temporal biodistribution of BPA-f in the
normal mouse brain.
3.1.2. Materials and Methods
Two sets of experiments were conducted. Approximately 10-week old female
C57BL/6 mice were given a bolus injection of BPA-f (250 mg BPA-f/kg body weight or
350 mg BPA-f/kg body weight) through the tail vein using a 26G needle. Tail vein
injection is more easily accomplished if the tail of the mouse has been warmed up. This
can be accomplished by shining a heating lamp on the tail for a few minutes, causing
expansion of the tiny veins on the sides of the tail. The obvious vessel observable on the
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top surface of the tail is an artery, and should not be used for this purpose. The mouse is
not anesthetized for tail vein injection because anesthesia will constrict the vessels.
For the 250 mg/kg group, five mice were sacrificed at each of the 6 different time
points (5, 10, 15, 30, 60, and 120 min after injection); for the 350 mg/kg group, data
points at 240 minutes after injection were also collected. After anesthesia (intraperitoneal
Pentobarbital, 30 mg/kg body weight), the mouse is pinned spread-eagle on a wooden
cutting board, and cardiac puncture is performed at the designated time points to collect
blood samples. The procedures for cardiac puncture are as follows: 1) A pair of sterile
tweezers with teeth is used to pick up the skin of the abdomen. The skin is cut below the
diaphragm, across the width of most of the abdomen. 2) The abdominal muscle is cut
slightly below the diaphragm to expose the abdominal cavity. 3) A cut is made through
the diaphragm into the thoracic cavity to expose the heart. 4) The heart is penetrated at
the apex with a heparinized 26G needle, and as much blood as possible is aspirated,
usually no more than 0.5 ml. The blood is then deposited into a purple top specimen
tube. The whole procedure, from the initiation of anesthesia to deposition of blood into
tube, takes less than 5 minutes. The brain tissues were removed post mortem, and
divided into right cerebrum, left cerebrum, cerebellum, brain stem and intracranial
nerves. The blood was analyzed for 10B concentration via the PGNAA method, while the
tissues were analyzed for 10B concentration by ICP-AES.
3.1.3 Results and Discussions
A total of sixty-five C57BL/6 mice were used for the normal neural tissue spatial
distribution study. Thirty mice received 250 mg BPA-f/kg body weight, and thirty-five
received 350 mg/kg via a bolus tail vein injection. Two separate experiments with
different BPA-f doses were done to study the effect of different dose regimens on the
biodistribution of BPA-f in normal brain. The BPA doses chosen correlate with the two
dose regimens employed in the Harvard-MIT Phase I clinical trials. The clinical trials
initially started with 250 mg BPA-f/kg body weight infused over 60 minutes. The
concentration was later increased to 350 mg BPA-f/kg body weight infused over 90
minutes to increase the average 10B concentration during irradiation. The 250 mg/kg
cohort was sacrificed at 5, 10, 15, 30, 60, and 120 minutes after injection. The 350
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mg/kg group was sacrificed at 5, 10, 15, 30, 60, 120, and 240 minutes after injection.
The blood samples were analyzed for 10B concentration with the PGNAA method. The
10B distributions in blood as a function of time for the two concentrations of BPA-f
infused are shown in figure 3.1. The mouse blood curve is remarkably similar to that of
the human blood biodistribution curve[12, 13], with the characteristic bi-exponential
decay. The rapid decline corresponds to redistribution of BPA-f throughout the body,
while the more gradual loss of BPA-f is attributed to renal excretion.
Murine Blood B-10 Concentration vs.
Time After Infusion for Two Different Doses
40 - ---------------------- --- 3 50 mg BPA-f/kg weight .-
- 250 mg BPA-f/kg weight
0
cm)
20 ........... ......................... ...........................................
0
0 50 100 150 200 250
Time After Infusion (min)
Figure 3.1 10B concentration (ppm) in blood as a function of time following a bolus tail
vein injection of either 250 mg BPA-f /kg body weight or 350 mg BPA-f /kg body
weight.
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The neural tissues were removed at the time of sacrifice, and were separated into
right cerebrum, left cerebrum, cerebellum, brain stem, and intracranial nerve. Figure 3.2
shows that in the 350 mg/kg group, the cerebellum has consistently higher 10B
concentration than other anatomic sites. The intracranial nerve also has a slightly higher
1B concentration at all time points studied as compared to cerebrum and brain stem. The
finding that there is a slightly higher 10B concentration in the intracranial nerve, a
radiation sensitive organ, might have important treatment planning implications.
Although due to the fact that the intracranial nerve is very small, it probably will not have
any significant impact on the radiation transport calculations, the dose received by the
intracranial nerve will simply have its 10B dose component scaled. However, if the dose
to the intracranial nerve increases substantially as a result of increased '0B concentration,
special care will have to be taken to minimize dose to the cranial nerves, which have
important sensory and motor functions in the CNS. To examine the possible effect of the
higher 10B concentration obtained in the intracranial nerve, a treatment plan was
simulated using MacNCTPlan[ 14], a treatment planning software developed at the
Harvard-MIT BNCT Program, and the resulted isodose contour is shown in figure
3.3[15]. In this simulation, the CT scans from one of the human subjects from the
Harvard/MIT Phase I clinical trial was used. Since it is difficult to outline all the
intracranial nerves, the optic tract was outline as the "tumor" region, and was assigned a
B concentration 1.3 times that of the normal brain, which is customary assigned a value
of 15 ppm in the clinical trial. The Fission Coverter Beam spectrum was used as the
irradiation source. From figure 3.3, it is apparent that the higher 10B concentration of the
optic nerve has little effect on the dose it receives. The dose received by the ipsilateral
optic nerve changes from 70% to 80, and the dose received by the optic chiasm changes
from 60% to approximately 67% of the prescribed maximum normal brain dose.
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Figure 3.2 10B concentration(ppm) in blood and various murine normal neural tissues as
a function of time following a bolus tail vein injection of 350mg BPA-f/kg body weight.
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Figure 3.3 Isodose contour of optic tract and normal brain under irradiation with FCB
Figure 3.4 shows the 10B distribution in blood and in normal neural tissues
(averaged between right cerebrum, left cerebrum, and brainstem) as a function of time for
the two concentrations of BPA-f, with the 250 mg/kg data points scaled to 350 mg/kg.
They demonstrate a linear relationship between the BPA-f dose administered and the 10B
concentrations obtained in blood and normal neural tissues.
Murine Blood and Normal Brain B-10 Concentration
vs. Time After Injection for 2 Doses with
250 mg/kg scaled to 350 mg/kg
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Figure 3.4 Blood and normal brain 10B biodistribution (ppm) following a bolus tail vein
injection of BPA-f
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As mentioned in section 2.2, researchers studying amino acid transport have long
employed multi-compartment models for because they are very useful to study the
pharmacokinetics of amino acids. Recently, Imahori[16] conducted cranial PET studies
of human glioma subjects using 18F- BPA. To explain the pharmacokinetics of the PET
data, a 3-compartment model was used, which consisted of a plasma compartment, an
extracellular compartment, and an intracellular compartment. From these PET data, the
various rate constants were obtained for nonnal brain tissue and for glioblastoma
multiforme. The same normal tissue rate constants were used in conjunction with blood
data from mice to predict the normal brain tissue 10B concentrations in mice, to determine
whether mice have similar BPA-f metabolism to humans. Figure 3.5 shows the predicted
normal brain 10B temporal distribution and the murine experimental data points for both
BPA-f doses administered.
Mouse "B Data, Imahori PET Model Prediction, BV=6%
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Figure 3.5 Predicted and experimental normal neural tissue 10B concentrations
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Figure 3.5 shows that there is excellent agreement between the experimental
values for normal murine brain and the prediction using the rate constants obtained from
human PET analysis. It is not clear why the earlier data points do not match as well as
the later time points. However, it might be due to the fact that the PET study was
conducted with a bolus injection of a trace amount of 1 8F-labeled BPA, while in the
animal study the mice received a much larger bolus injection (250 mg/kg weight to 350
mg/kg weight).
From these experimental results, several conclusions can be reached. First, the
human and mouse blood ' 0B concentration curves are similar in form; both express a
characteristic bi-exponential decay, showing that the BPA-f metabolism/transport in
blood is similar for both. Second, in the range of BPA-f dose currently used in the
clinical trial, there is a linear relationship between the amount of BPA-f administered and
the final 10B concentrations reached in blood and normal brain tissues. Third, there seems
to be some variation between the '0B concentrations observed in the different parts of the
brain; in particular, the cerebellum and the intracranial nerve 10B concentrations are
slightly higher than that observed in the right and left cerebrum, and the brainstem. An
issue was raised regarding the time the cerebellum and the intracranial nerve were
weighed. Since these tissue samples weigh less than the right and left cerebrum, and the
brainstem, it is possible that with longer time interval between the time the tissues were
harvested and stored in sealed eppendorf tubes and the time they were weighed, the water
contents of these tissues might have changed due to drying of the samples. With the
smaller samples, the drying effect would be more pronounced. Unfortunately, no
experiments were conducted to study this possibility. However, since the observation
that the intracranial nerve has higher "0B concentrations, if confirmed, can have far-
reaching implications, therefore, a treatment plan was simulated. It appears that with the
FCB, the resulting dose to the optic chiasm is not significantly higher than the
surrounding normal brain tissues. This small increase in the optic tract dose due to higher
10B concentration may still have important clinical implication with increased radiation
dose. Special care during treatment planning will have to be taken to avoid doses to the
optic tract when the dose reaches 8 - 9 Gy, which is the tolerance dose of the optic tract
51
to single fraction radiation. In addition, although it does not appear to have significant
effect, the finding that a higher '0B concentration is reached in the intracranial nerve
should be verified by a larger and more robust animal model. Finally, once the
appropriate metabolism rate difference, namely the time scale difference between human
and mouse, has been taken into account, there is not much difference observed in the
normal brain metabolism of BPA-f between humans and mice. In fact, the '0B
concentrations predicted by the pharmacokinetic rate constants obtained from human
PET studies correlate well with the '0B concentrations measured in the mouse normal
brain. Therefore, this murine model could be used to study the pharmacokinetics of
BPA-f in normal brain tissues, and could may be a good model for studying the late
radiation effects of boron neutron capture therapy in the CNS.
3.2 BPA-f Pharmacokinetics in An Intracranial Murine
GL261 Glioma
3.2.1 Introduction
As mentioned previously, the selective localization of 10B in the tumor is of great
importance to the success of BNCT, as is the absolute amount of 10B in tumor as well as
the tumor-to-blood and tumor-to-normal tissue 10B concentration ratios. Animal studies
have demonstrated that Boronophenylalanine (BPA) is taken up preferentially by
different tumors[17], including melanoma[18] and rat 9L gliosarcoma[19]. Almost all
the animal studies examining BPA biodistribution and BNCT radiation effect on tumor
and normal brain have used the rat 9L gliosarcoma model. However, since previous
work in this laboratory by Dr. Solares[20, 21] used the murine glial tumor GL261, it was
once again selected as the system to be studied. In the previous GL261 experiments in
this laboratory, intracerebral tumor was induced by inoculating the mice with GL261
tumor fragments grown in the flanks of other C57BL/6 mice. In the present work, the
GL261 cells used for inoculation were grown in vitro. Single cell suspension inoculation
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has the advantage that the tumor will grow more dispersively and not be confined to the
location of the tumor fragment.
3.2.2 Materials and Methods
Murine Glioma Model: Cryopreserved tumor fragments of the mouse glioma
GL261 cell line were obtained from the Division of Cancer Treatment and Diagnosis
Tumor Repository at the National Cancer Institute (Frederick, Maryland). This is a
primary mouse brain tumor cell line that was induced in the brains of C57BL/6 mice after
intracerebral implantation of methylcholanthrene pellets.
Tumor Cell Growth in Tissue Culture: The tumor fragments came in frozen
vials shipped in dry ice. The vial is thawed by immersion in a 37'C waterbath for up to 1
minute; if the vial is kept in the waterbath for longer than 1 minute, the DMSO present in
the freezing medium will kill the cells. The vial is quickly wiped with a paper towel
saturated with 70% ethanol and brought into a laminar flow hood that has been
thoroughly wiped down with 70% ethanol. Careful aseptic technique is important
throughout the procedure. The contents of the vial is rapidly poured into a 15 ml conical
centrifuge tube containing 10 ml of Dulbecco's Modified Eagle Medium (DMEM with
4.5 g/L Glucose; GIBCO Laboratories Life Technologies Inc., Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS, heat inactivated in a 60'C water bath
for 30 minutes; SIGMA Chemical Company, St. Louis, MO). The cells are centrifuged
for 2 minutes at 1000 RPM; the fetal bovine serum will neutralize the effect of the
DMSO and help to reduce the damage to the cells. The supernatant is discarded using a
sterile glass pasteur pipet, and the tumor fragments are placed in a 100 mm culture dish.
The tumor is minced into small pieces with a sterile scalpel and placed in a 50 ml
centrifuge tube containing 20 ml DMEM. After centrifuging the tumor pieces are
allowed to settle and the supernatant is poured off. The following reagents are added; 8
ml of DMEM, 1 ml of collagenase (4500 U/ml; Sigma Chemical Company, St. Louis,
MO) and 1 ml of DNAse (1 mg/ml; Sigma Chemical Company, St. Louis, MO). The
cells are then incubated at 37'C for 10 minutes in a shaking waterbath and spun at 1000
RPM for 5 minutes; the supernatant is discarded. The cells are resuspended in a solution
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containing DMEM, collagenase and DNAse as before, and are then incubated at 37'C for
15 minutes in a shaking waterbath. Additional 1 ml DNAse is added to the cells. The
cells are then agitated for another 5 minutes at 37'C in a shaking waterbath, and filtered
through a piece of sterile gauze into a 15 ml centrifuge tube to remove clumps. This
whole procedure will break up the tissue fragments and release individual cells. The cells
are spun for another 5 minutes at 1000 RPM and resuspended in 10 ml DMEM. After
being vortexed a little, the cells are spun for 5 minutes at 1000 RPM and the supernatant
is discarded. Finally, the cells are resuspended in 10 ml DMEM with FBS, and placed
into 2 or 3 100 mm cell culture dishes which are incubated at 5% CO2 and 37'C.
The culture dish is checked for cell growth every couple of days. Initially, the
dish should not be moved so that the cells will have a chance to attach to the bottom of
the dish and grow. The medium is chanced when it turns color from pink or red to
orange. The cells are maintained in Dulbecco's Modified Eagle Medium (GIBCO
Laboratories Life Technologies Inc., Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS; SIGMA Chemical Company, St. Louis, MO), 1% L-Glutamine
(GIBCO), 100 units/ml of penicillin G (GIBCO) and 100 mg/ml streptomycin
(GIBCO)(2). When the cells become confluent, cells are split using the following
procedures. First, the flask is removed from the incubator and placed into the hood. The
old medium is asparated out using a sterile glass pasteur pipet. For a 75 cm 2 culture
flask, 2 ml of cell dissociation solution (SIGMA Chemical Company, St. Louis, MO) is
added, for a 150 cm 2 culture flask, 3 ml of cell dissociation solution is added. The flask
is returned back to the incubator for 3 to 5 minutes. The cell dissociation solution is
gentler to the cell membranes than the trypsin usually used in cell culture work. The
flask is then removed from the incubator, shaken and agitated for a short while so the
cells will detach from the bottom of the flask. The sides and the bottom of the flask are
rinsed by adding 8 ml of medium. By pipetting up and down a few times, the cell clumps
are broken up into single cell suspension. A couple of new flasks are brought into the
hood, for a 75 cm 2 culture flask, 1 ml of the cell suspension is added to 20 ml of medium,
for a 150 cm 2 culture flask, 1 ml of the cell suspension is added to 30 ml of medium. The
medium is gently swirled around the flask so the cells will be homogeneously mixed, the
new flasks are then returned to the incubator.
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Generation of Brain Tumors: For the initiation of an intracranial tumor, a 10
week old female C57BL/6 mouse (Taconic, Germantown, NY) was anesthetized
(intraperitoneal Pentobarbital, 30 mg/kg body weight), and the head was shaved. Using
aseptic technique, the scalp was incised, and the tumor cell suspension (4 x 104 cells in
0.02 ml of medium) injected into the mouse skull at a point 4 mm to the left of the
midline and 2 mm above the bregma at a depth of 4 mm using a 30-gauge needle. This
technique resulted in a locally expanding tumor in most of the mice (- 80% take rate). If
no stereotactic positioning apparatus is available, the inoculation is done as follows: the
30G needle is held vertically, and used to drill a hole into the skull and the dura at a
position just posterior to the coronal suture and lateral to the midline. When the bevel of
the needle is just totally immersed, approximately 4 mm deep, the cell suspension is
slowly injected into the brain. Approximately 2 - 3 weeks after tumor implantation, the
mice are then given a BPA-f (350 mg/kg) bolus tail vein injection.
Experimental Procedure: Approximately 12 week old female C57BL/6 mice
were given a bolus injection of BPA-f (350 mg BPA-f/kg body weight) through the tail
vein using a 26G needle. Figure 3.6 shows a mouse hunched over and sitting in one
corner of the cage, typical signs to look for when trying to determine whether a tumor has
grown inside a mouse's brain. Lack of appetite, lethargy, and an obvious hunch in the
back, usually indicate that a sizable tumor; the hunched back occurs when the meninges
become infected or are invaded by foreign cells.
Three or four mice were sacrificed at each of 7 different time points (5, 10, 15, 30,
60, 120 and 240 minutes after injection), with additional 1 or 2 mice sacrificed at various
time points such as 40, 90, and 180 minutes. Cardiac puncture as discussed in section
3.1.2 was performed to collect blood samples. The tumor tissue and normal brain tissues
were removed post mortem, and separated into right cerebrum, left cerebrum, cerebellum,
brainstem, intracranial nerves and tumor. The blood 10B concentration was analyzed by
PGNAA method, and the tissues were analyzed for 10B concentrations by ICP-AES after
being acid-digested.
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Figure 3.6 A picture of a mouse displaying typical signs of having an intracranial tumor.
Note the hunched back.
3.2.3 Results and Discussion
For this set of experiments, 12 weeks old female C57BL/6 mice bearing
intracranial glioma tumor GL261 were injected with 350 mg BPA-f/kg body weight via a
single bolus through the tail vein, and were sacrificed at the various time points. The
blood, normal brain tissue and tumor were removed and analyzed for 10B concentration.
The time dependence of 10B accumulation in glioma tumor and normal brain tissue is
shown in figure 3.7, and their ratios are shown in figure 3.8. It can be seen from figure
3.7 that GL261 cells quickly take up BPA-f after injection, with the 10B concentration in
GL261 cells up to 8-11 times that of normal brain tissue at 5 -15 minutes after BPA-f
injection. Both the tumor: blood and tumor: normal brain 10B concentration ratios vary
with time. The 10B concentration in GL261 tumor rapidly decreases for later time points,
it becomes about 5 times higher than that of normal brain at around 60 minutes, and
further decreases to approximately only 2 times higher than brain at 240 minutes after
injection. However, the 10B concentration in GL261 tumor is consistently higher than
the 10B concentration in normal brain tissues at all times studied. This is qualitatively
consistent with human GBM biopsy data[22], although the ratios obtained in GL261 and
in human glioblastoma are different. This may due to the fact that in glioblastoma
biopsies, the extent of necrosis in the tumor is not known. As shown by Coderre[22],
tumor ' 0B concentration correlates with the cellularity of the tumor samples. It may also
due to the fact that tumor vascularity varies among different tumor lines. However, this
result confirmed that blood, normal brain, and tumor all have quite different BPA-f
pharmacokinetics. A detailed knowledge of the pharmacokinetic behaviors of these
tissues could have important practical implications for treatment planning.
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Figure 3.7. Boron concentration (ppm) in blood, brain and GL261 tumor as a function of
time following a bolus tail vein injection of 350 mg BPA-f /kg body weight.
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Figure 3.8 10B Concentration Ratios for Intracranial GL261/Blood, Intracranial
GL26 1/Normal Brain, and Normal Brain/Blood.
By using the 3-compartment model detailed in section 2.3, and by minimizing the sum of
the squares of the residues, the rate constants for the compartment-model of BPA-f
pharmacokinetics for normal brain and GL261 tumor were obtained. The values for k1
through k4 for the normal brains are 0.01 ml/g/min, 0.25 min, 0.033 min~1 and 0.011
min~', respectively, which are very close to those observed by Imahori[16] in the human
PET studies (0.011 ml/g/min, 0.025 min', 0.033 min~' and 0.009 min~, respectively).
The values for k1 through k4 for the GL261 tumors are 0.178 ml/g/min, 0.181 min,
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0.091 min~1, and 0.036 min~', respectively. These values differ substantially from the
values Imahori obtained for GBM, which are 0.027 ml/g/min, 0.041 min, 0.029 min~'
and 0.013 min', respectively. There are several reasons why these values are different.
The first is that different tumor lines were used; differences in BPA-f uptake metabolism
can contribute to the differences in influx and efflux rates. In addition, the vascularity of
the tumor lines is different. Lastly, the PET study averaged over large tumor areas
including necrotic areas, while the GL261 is well vascularized; this factor likely
contributed to different observed 10B concentrations and the distinct pharmacokinetics.
Figure 3.9 shows the experimental data and the fit of the 3-compartment model using the
k's derived. Figures 3.10 and 3.11 are hemotoxlyn and eosin stained histological sections
of both normal brain and GL261 tumor. They are included to demonstrate the vast
differences in nuclear mass and growing pattern between normal brain and tumor.
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Figure 3.9 Experimental data of GL261 tumor and normal brain fitted to the three-
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Figure 3.10 H & E stained histological section of normal murine brain.
Figure 3.11 H & E stained histological section of GL261 murine glioma tumor
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3.3 BPA-f Pharmacokinetics Study in B16 Melanoma bearing
Murine Brains
3.3.1 Introduction
In addition to Glioblastoma Multiforme, intracranial metastatic melanoma is
another tumor type currently under investigation in the Harvard-MIT Phase I clinical
trial. From the results of two subjects with intracranial melanoma, BNCT appears to be
promising for the treatment of such disease[23]. This observation is in line with the data
collected from various human and animal models of melanoma[18, 24-26]. Melanoma is
a cancer cell line that exhibits excellent uptake and accumulation of BPA. However, as
in the case of glioblastoma multiforme, to be able to treat intracranial melanoma
effectively without exposing the normal brain to high doses of radiation, it is important to
know the full pharmacokinetics of BPA-f in intracranial melanoma tumor and its
relationship to blood and normal brain BPA-f pharmacokinetics. The combined results
from the BPA-f pharmacokinetics of two different intracranial tumors could provide
insights into the transport and the pahrmacokinetics of BPA-f in general.
3.3.2 Materials and Methods
Murine B16 Melanoma Model: B16 murine melanoma cells were obtained from
the Department of Cancer Pharmacology at Dana Farber Cancer Institute, courtesy of Dr.
Emil Frei's laboratory. The tumors were removed aseptically from the flanks of
C57BL/6 mice (Taconic, Germantown, NY). Using the same method detailed in section
3.2.2 for harvesting single tumor cells from tumor fragments, a B 16 tumor cell
suspension was obtained. Tumor cells were then grown and maintained in Dulbecco's
Modified Eagle Medium (DMEM with 4.5 g/L Glucose; GIBCO Laboratories Life
Technologies Inc., Grand Island, NY) supplemented with 10% fetal bovine serum (FBS;
SIGMA Chemical Company, St. Louis, MO), 1% L-Glutamine (GIBCO), 100 units/ml of
penicillin G (GIBCO) and 100 mg/ml streptomycin (GIBCO).
Generation of Brain Tumor and Subcutaneous Tumor: For the initiation of
intracranial tumor, a 10 week old female C57BL/6 mouse (Taconic, Germantown, NY)
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was anesthetized (intraperitoneal Pentobarbital, 30 mg/kg body weight), and its head was
shaved. Using aseptic technique, the scalp was incised, and the tumor cell suspension (4
x 104 cells in 0.02 ml of medium) was injected into the mouse skull at a point 4 mm to
the left of the midline and 2 mm above the bregma at a depth of 4 mm using a 30-gauge
needle. This technique resulted in an invasively expanding tumor in all of the mice. Half
a million cells were also injected into the subcutaneous area above the right hind leg of
the mice. Approximately 10 - 16 days after tumor implantation, the mice were then
given a BPA-f (350 mg/kg) bolus tail vein injection.
Experimental Procedure: Approximately 12 week old female C57BL/6 mice
were given a bolus injection of BPA-f (350 mg BPA-f/kg body weight) through the tail
vein using a 26G needle. Five mice were sacrificed at each of 7 different time points (5,
10, 15, 30, 60, 120 and 240 minutes after injection). Cardiac puncture was performed to
collect blood samples. The tumor tissue and normal brain tissues were removed post
mortem, and separated into right cerebrum, left cerebrum, cerebellum, brain stem and
intracranial nerves. For animals with sizable subcutaneous melanoma lesions, the
subcutaneous melanoma and skin were also removed for analysis. The blood was
analyzed by PGNAA and the tissues were first acid-digested and then analyzed by ICP-
AES.
3.3.3 Results and Discussion
For this set of experiments, 12 week old female C57BL/6 mice bearing
intracranial melanoma tumor B16 were injected with 350 mg BPA-f/kg body weight via a
single bolus through the tail vein, and were sacrificed at the various time points. The
blood, normal brain tissue and B16 tumor were removed and analyzed for 10B
concentrations. Some of the animals also had sizable subcutaneous melanoma tumor
nodules (50 mg< tumor weight< 100 mg) in their right flanks; the skin and subcutaneous
melanoma from these animals were also analyzed. Although the B 16 tumors are more
easily visualized than the GL261 tumors due to their black color, the B 16 tumors are
more difficult to remove because although some animals have localized tumors, most
animals have tumors that tend to spread along the meninges and are less localized than
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the GL261 tumors. Figure 3.12 shows a murine brain with intracranial B16 melanoma,
and figure 3.13 shows a murine brain with intracranial GL261 glioma tumor. It is clear
that not only are the color and growth pattern of the 2 tumors different, the morphology
of the tumor cell also looks different, therefore, it is possible that their BPA-f
pharmacokinetics may also be different.
Figure 3.12 Murine Brain with intracranial B 16 Melanoma.
Figure 3.13 Intracranial GL261 glioma tumor.
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The time dependence of 10B accumulation in intracranial B16 tumor, normal brain
tissue, subcutaneous melanoma and skin is shown in figure 3.14, with the ratios shown in
figure 3.15. It can be seen that B16 cells quickly take up BPA-f after injection, with the
10B concentration in B 16 cells reached up to 8-10 times that of normal brain tissue at 15
minutes after BPA-f injection. Similar to GL261 glioma tumor, both the tumor: blood
and tumor: normal brain 10B concentration ratios vary with time, although in this case,
the 10B concentration in B16 tumor does not decrease as rapidly as in GL261, the B16
tumor still has 5 times higher 10B concentration than in normal at 240 minutes after
injection. At all times, the 10B concentration in B16 tumors is consistently higher than
the 10B concentration in normal brain tissues, which is qualitatively consistent with the
human GBM biopsy data[22], the human melanoma data[27] and the GL261 glioma
tumor model. This difference could be due to the different tumor cell lines with their
different metabolism requirements and vascularity. However, this result confirmed again
that blood, normal brain and tumor all have quite different BPA-f pharmacokinetics. A
detailed knowledge of the pharmacokinetic behaviors of these tissues has practical
implications for treatment planning. It is also observed that the subcutaneous melanoma
has consistently lower 10B concentration than the intracranial melanoma. One possible
explanation could be that there are differences in vascular supplies between the two
environments, although there is not sufficient data points to conclude statistically.
Additional observations show that for all time points studied, the subcutaneous melanoma
'
0B concentration is approximately 2 times that of skin, while at 30 minutes after
injection, the subcutaneous melanoma is about 3 times of the 10B concentration in skin.
Again, by using the 3-compartment model detailed in section 2.3, and minimizing
the sums of the squares of the residues, the rate constants for the compartment-model of
BPA-f pharmacokinetics for normal brain and B 16 tumor were obtained. The values for
kl through k4 for the normal brains are 0.009 ml/g/min, 0.25 min-, 0.033 min' and
0.011 min-1 , respectively, which are very close to that observed by Imahori[16] in the
human PET studies (0.011 ml/g/min, 0.025 min-1, 0.033 min-' and 0.009 mid',
respectively). The values for kl through k4 for the B16 intracranial melanoma are 0.262
ml/g/min, 0.211 min', 0.058 min, and 0.011 mim-1. These values differ substantially
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from the values Imahori obtained for GBM, which are 0.027 ml/g/min, 0.041 min-',
0.029min-1 and 0.013 min-, respectively; they also differ from the values obtained from
the GL261 tumors, which are 0.178 ml/g/min, 0.181 min-1, 0.091 min-', and 0.036 min-1,
respectively. These results are summarized in table 3.1. The most notable difference
between the GL261 and the B16 is the initial influx across the blood-brain-barrier, and
the efflux from the intracellular compartment. One possible explanation could be as
follows: since BPA-f is an analogue of the melanin precursor, the B16 cells will have
more transport carriers on their cell membranes, thereby contributing to the higher influx
rate initially. However, it is conceivable that once the precursors get into the cells, they
are rapidly converted to melanin and bound inside the cell. Therefore, the efflux from the
intracellular compartment will decrease. The results of fitting the B 16 experimental data
using the k's derived from the 3-compartment model is shown in figure 3.16.
Tissue kI (ml/g/min) k2 (min-') k3 (min-1) k4 (min')
GBM (n=6)* 0.027±0.07 0.041±0.018 0.029±0.008 0.013±0.007
GL261 (n=6) 0.178±0.025 0.181±0.037 0.091±0.013 0.036±0.009
B16 (n=6) 0.262±0.042 0.211±0.031 0.058±0.015 0.011±0.006
Normal Brain
Human (n=16)* 0.011±0.003 0.025±0.010 0.033±0.015 0.009±0.011
GL261 (n=6) 0.010±0.004 0.025±0.009 0.033±0.009 0.011±0.006
B16 (n=6) 0.009±0.003 0.025±0.007 0.033±0.010 0.011±0.003
Table 3.1 ki through k2 values for GBM[16]
* Data from Imahori PET study[16]
, GL261 and B16 tumors
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Figure 3.14 10B concentrations in intracranial B16 melanoma, normal brain,
subcutaneous melanoma and skin after a 350 mg BPA-f/kg weight bolus injection
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Figure 3.16 Experimental data from averaged B16 intracranial melanoma and nonnal
brain fitted to the 3-compartment model
Figure 3.17 and 3.18 are the predicted 10B concentration ratio between turmor and
normal brain, tumor and blood, and normal brain to blood using the three-compartment
model and the rate constants derived. It is apparent that the normal to blood ratios for
both GL 16 and B 16 are very similar, while the tumor to blood and tumor to normal brain
ratios between the two systems are different. They further demonstrate that for different
tumor cell lines, the BPA-f pharmacokinetics is different.
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3.4 BPA-f Pharmacokinetics study in CXO1 Hepatic Colorectal
Metastasis
3.4.1 Introduction
In 1998 more than 150,000 Americans will be diagnosed with colorectal cancer,
and over 60,000 will die from this tumor. 15 - 25% will have hepatic metastases at the
time of diagnosis, and another 20 - 30% will develop metastatic hepatic lesions
subsequent to resection of the primary tumor. Treatment options for hepatic metastases
include aggressive surgical resection, administration of regional chemotherapeutic agents,
systemic chemotherapy, radiotherapy, or other palliative and experimental procedures.
Despite well-defined pharmacological benefits of selected chemotherapeutics, there is no
convincing survival advantage for many of the above mentioned techniques[28-30]. The
median survival after diagnosis is typically 22-24 months, and has changed minimally
over the past decade.
Colorectal metastases are hypovascular and can continue to grow under hypoxic
conditions. Thus, the use of an actively transported boron-containing compound
selectively localized in tumor and the high-LET radiation produced by BNCT could be a
useful therapeutic approach to this clinical problem. This approach has previously been
considered by the BNCT group at the University of Pavia, in Italy, where animal
experiments were conducted using boric acid, sodium borocaptate (BSH), and '0B-
conjugated tetraphenyl porphyrin sulfonate (TPPS)[31]. Toxicity and biodistribution
studies following intravenous injection of these compounds were performed. More
recently, they have conducted an experiment in which diffused hepatic metastases were
induced in BD-IX rats, the rats were then given autotransplantation and their livers
underwent BNCT procedures[32]. In this experiment, they used BPA-f with a dose of
300 mg BPA/kg weight. The 300-second irradiations occurred 2-3 hours after BPA
administration. The tumor to normal liver ratio they detected was 3.9[32].
In the present study, a well-characterized animal model employing the athymic
mouse was used to gain information on the biodistribution of Boronophenylalanine-
fructose (BPA-f ) in hepatic colorectal metastases and normal liver tissue as a function of
time. The goal was to investigate whether BPA-f has a preferential uptake in hepatic
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colorectal metastasis. If the tumor does possess preferential uptake relative to normal
liver, BNCT could be a plausible treatment alternative for the treatment of hepatic
colorectal metastasis.
3.4.2 Materials and Methods
The CX-1 hepatic colorectal metastasis model: Tumor cells were grown and
harvested in collaboration with the Tumor Biology Lab of the Department of Cancer
Biology at the Beth Israel Deaconess Medical Center. The CX-1 is a human colon cancer
cell line. The cells are maintained in RPMI 1640 medium (GIBCO Laboratories Life
Technologies Inc., Grand Island, NY) with 10% fetal bovine serum (FBS; SIGMA
Chemical Company, St. Louis, MO), 1% L-Glutamine (GIBCO), 100 units/ml of
penicillin G (GIBCO) and 100 mg/ml streptomycin (GIBCO). For the inoculation of
tumor into animals, 107 cells/ml phosphate buffered saline at pH 7.4 is used
Generation of Hepatic Tumor: For the initiation of hepatic tumors, 10 week old
female athymic nude mice (Taconic, Germantown, NY) were first anesthetized
(intraperitoneal injection of Pentobarbital, 30 mg/kg body weight), and a small left
subcostal incision was made. After gently teasing the spleen out using a pair of tweezers,
0.1 ml of the cell suspension (107 cells/ml phosphate buffered saline in pH 7.4) was
injected into the spleen of the mouse using a 26-gauge needle. Due to the fact that the
spleen shares blood supply with the liver, intrasplenic injection of tumor cells will result
in multiple hypovascular metastases which will be well established 6 weeks after
implantation. The tumor take rate is -80%.
Experimental Procedures: Thirty five 16 week old female athymic nude mice
bearing hepatic colorectal metastases were given a bolus injection of BPA-f (350 mg
BPA-f/kg body weight) through the tail vein using a 26G needle. This is the same dose
as is currently being used in the Harvard-MIT BNCT clinical trial. Five mice were
sacrificed at each of the 7 different time points (5, 10, 15, 30, 60, 120, and 240 minutes
after injection). Cardiac puncture was performed to collect blood samples. Samples of
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skin, tumor and normal liver tissues were removed after the death of the animal. The
blood 10B concentration was analyzed using PGNAA, while the tissues were first acid
digested, then analyzed for their 14B concentrations using ICP-AES.
3.4.3 Results and Discussion
Thirty five athymic nude mice bearing hepatic colorectal metastasis were used for
the BPA-f biodistribution studies. Most mice had multiple metastatic nodules while a
few had more than half of their livers replaced by tumor. They all received a bolus
injection of BPA-f (350 mg BPA-f /kg body weight) through the tail vein. They were
separated into 7 groups and sacrificed at the prescribed time points (5, 10, 15, 30, 60,
120, and 240 min after injection). Blood samples were drawn at sacrifice and analyzed
using PGNAA. Samples of skin, normal liver, and tumor were collected after death and
were analyzed by ICP-AES after acid-digestion. Figure 3.19 shows the time dependence
of boron accumulation in blood, skin, normal liver, and tumor. It is clear that both the
skin and the normal liver follow a similar time course as the blood, which is to be
expected since they are both highly vascularized organs. It was speculated that due to the
hypovascular nature of the hepatic colorectal metastasis, the boron accumulation in the
tumor lagged behind that of the normal liver, but quickly built up and surpassed that of
the normal liver. From figure 3.20, it is shown that at 15 min after the bolus injection the
metastases had 1.5 times the boron concentration in blood, increasing to approximately
2.5 times by 60 min after injection, and decreasing again to about 1.5 times at 240 min.
Similar trends were observed for tumor/normal liver, and tumor/skin. Tumor boron was
approximately 1.3 times that in normal liver at 15 min, 1.8 times at 30 min, 2 times at 60
min and 120 min, and barely 1 at 240 min after the bolus injection. However, the skin
shows consistent higher 10B concentration than the blood, and since it is the first organ to
be penetrated by the neutron beam for liver irradiation, it might be important to examine
the effect of the elevated 10B concentration in the skin.
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Figure 3.19 10B biodistribution in blood, normal liver, hepatic colorectal metastasis and
skin.
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Figure 3.20 0B biodistribution ratio for CX-1/blood, CX- 1/normal liver, CX- 1/Skin,
Normal Liver/Blood, and Skin/Blood.
Calculations were carried out to quickly estimate significance of an elevated skin
10B concentration. Due to the unavailability of a realistic liver/body model, the
ellipsoidal head phantom was used. The FCB dose profile in the ellipsoidal head
phantom was used in the calculations[151, the skin was assumed to span from 0 to 1 cm
and the liver from 2 cm to the edge of the phantom, with the higher 10B concentration
employed for skin (27 ppm) and tumor (35.4 ppm). Since there are no RBE values
available for liver, the brain RBE values were used. Figure 3.21 shows the dose profile
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calculated in the head phantom. It appears that with the 10B concentration ratio achieved
and the high skin 10B concentration present, significant dose will be delivered to the skin
even with the deep penetrating FCB.
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Figure 3.21 Liver Dose Rate Profile from Fission Converter Neutron Beam[15]
Figure 3.22 and 3.23 are H & E stained histological sections of normal liver and
hepatic colorectal metastasis to demonstrate the different morphology of the two tissues.
In summary, to obtain a tumor therapeutric ratio of greater than unity in liver, a
highly vascularized organ, represents a challenge for BNCT. Nevertheless, in the present
study encouraging results for BPA-f uptake in hepatic colorectal metastases were
obtained. In the athymic mouse model, during 30 - 60 min after a bolus injection, the
differential uptake of BPA-f in the hepatic metastases and normal liver tissue was
approximately equal to 2 (T/NT). While this ratio is lower than that seen in experimental
brain tumor models, it is encouraging given the biology of this setting. The problem
seems to lie in the fact that skin also has higher 10B concentration than blood or normal
liver, therefore, the dose received by the skin may be high and become the limiting organ
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for toxicity. Additional research will have to be conducted to derive the RBEs for the
liver and the hepatic colorectal metastases. Once obtained, it will be possible to generate
detailed dosimetric calculations using realistic liver/body model, and to determine the
suitability of BNCT for the treatment of hepatic colorectal metastasis.
Figure 3.22 H & E stained histological section of normal liver tissue next to a
capillary.
Figure 3.23 H & E stained histological section of hepatic colorectal metastasis.
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3.5 Lung 1B Measurements
The M67 beam currently used in the Harvard-MIT BNCT Phase I clinical trial is a
vertical beam, and the subjects are sometimes positioned with their torso in close
proximity to the beam. Since the M67 beam has considerable fast neutron contamination,
with this kind of positioning it is conceivable that some radiation damage might occur if
BPA-f uptake is significant in either the heart or the lungs. This issue becomes
increasingly important as stepwise dose escalation has prolonged the total irradiation time
to 400 - 600 minutes. Therefore, an investigation into the BPA-f uptake in lungs was
initiated.
Lung samples from the GL261 murine glioma model study mice were collected
after they were sacrificed. These lung samples were collected in anticipation of a
possible study of lung dose, they were weighed, then stored in a -70' freezer in tightly
sealed eppendorf tubes. It was decided that the issue was important enough to warrant a
closer look. The samples were first acid-digested and analyzed for their 10B
concentrations using ICP-AES. The lung 10B concentrations were found to be 8-10 times
higher than the normal brain 10B concentrations during the late time periods (30-240
minutes after 350 mg BPA-f/kg weight bolus injection). More significantly, the 10B
concentrations in lungs do not seem to decrease with time. Figure 3.24 shows the results
of these lung samples.
The results were of such an extreme nature that verifications are required. The
issue of contamination was ruled out by measuring the' 0B concentration of the nitric
acid-sulfuric acid mixture and the Triton X-100 solutions used for acid-digestion.
PGNAA measurements showed that neither solution contained 10B.
77
10 B Concentration in Tissues
vs. Time After Injection
60
50
50 100 150
Time (min)
.. . ..
.. .
... .
.
.
.
.
.
.
.
-. I
... .. .. .. . ...... .. .............
- - - - - --.-..-....- - - -4 ....  . . .. .. . .. ........ ........
200 250
Figure 3.24 10B concentrations in blood, normal brain and lung tissue in GL261
bearing mice.
It was decided that a verification of the data was required. The animal study
being studied at this time was the B 16 intracranial melanoma model. Four lung samples
were collected and measured using PGNAA. Table 3.2 shows the results of the PGNAA
measurements.
It is worth noting that a calibration curve using only 0.05 ml of standards was
used for this measurement because the tissue samples were too small. By using
approximately the correct volume for standards, the 10B concentrations obtained using
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either the B/H method or using only the B peak count rates give similar results (table
2.2), with a maximum difference of 30%. Although these results still showed that lung
tissues did have higher 10B concentrations than blood and normal brain tissues, the factor
is only 4 - 5 times higher instead of 8 -10 as measured by ICP-AES.
Sample # Sample Weight Time (min) 10B Concentration
11 48.3 mg 9.5 29.8 ± 2.2 ppm
15 52.4 mg 16 23.2 ±1.7 ppm
32 37.9 mg 60 19.4 ± 1.4 ppm
31 48.4 mg 30 19.7 ±1.9 ppm
Table 3.2 PGNAA 10B measurements of lung tissues
To resolve the discrepancy between the lung 10B concentrations measured by ICP-
AES and that measured by PGNAA, another experiment was conducted. Since by this
time, there were no longer mice available that were carrying intracranial tumors, four
healthy mice were given bolus injections of 350 mg BPA-f/kg weight through their tail
veins. They were sacrificed at different time points, and their lungs were removed. The
results were shown in Table 2.3 in chapter 2 under PGNAA and ICP-AES
intercomparison. It reveals that for healthy mice, the lung 10B concentrations follow the
blood curve, with higher 10B concentrations for earlier time points and low 10B
concentrations for later time points.
It is apparent that there is no error in the lung 10B concentration measurements
obtained by ICP-AES or by PGNAA. The apparent discrepancy in the 10B concentrations
is most likely due to the health of the animals. For healthy mice, the 10B concentration in
the lungs appear to follow the blood pharmacokinetics and is approximately the same as
in the blood (with the exception of the early time point at 6 minutes). However, for mice
with intracranial tumors, the lung 10B concentrations do not seem to follow the blood
distribution. For mice with B16 intracranial melanoma, with a lung 10B concentration
approximately the same as blood, is 8 times that of the normal brain, as seen at the 10
minute time point. At the 60 minute time point, the lung 10B concentration is twice as
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high as the blood, but 4 times the 10B concentration in normal brain. The pattern might
be very different for a much later time point, such as 240 minutes after injection. For
mice with GL261 glioma tumor, only later time points were sampled so that no
observations are available for the earlier times. However, for the 30 minutes time points,
the lung 10B concentration is approximately 5-7 times of that seen in the blood, and
approximately 8-10 times of normal brain; for 240 minutes samples, the lung 10B
concentration is approximately 10 times higher than normal brain and blood. Tumor
bearing mice are smaller in size (14 g to 16 g as opposed to 22 g for healthy mice) and
more lethargic than healthy mice and are likely to have decreased food intake. No
explanation could be suggested for the lung 10B concentration difference, since the
experimental conditions were similar, with the only difference being the health status of
the animals.
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Chapter 4
Conclusions and Recommendations for Future Work
4.1 Conclusions and Discussion
From the experimental data presented in chapter 3, several observations can be
made regarding BPA-f pharmacokinetics. From the first set of experiments on normal
brain tissue, the conclusions are presented below:
(1) Within the current dose administration regimen, i.e. 250 - 350 mg BPA-f/kg
body weight there exists a linear relationship between the amount of BPA-f administered
and the 10B concentrations measured in blood and normal brain tissues. This linearity has
also been observed in human Glioblastoma biodistribution experiments albeit at lower
infusion concentrations[ 1]. Therefore, it is anticipated that a higher BPA-f dose would
result in a higher 10B concentration in tumor, resulting in a higher tumor radiation dose.
(2) There appear to be slight variations in the spatial BPA-f biodistribution in
normal brain tissues. While the right cerebrum, the left cerebrum and the brainstem all
have similar 10B concentrations, the cerebellum and the intracranial nerve consistently
have higher 10B concentrations throughout the time course studied. These regional
variations have also been observed in related neutral amino acids tyrosine and
phenylalanine where influxes differ in different brain structures [2].
Although the isodose contours produced using MacNCTPlan showed only small
effects, with the uncertainty in the RBEs used, the higher 10B concentration in the
intercranial nerve could still have practical dosimetric and treatment planning
implications, particularly as higher doses are reached. The result should be verified using
a larger animal model with higher spatial resolution. HRQAR experiments could also be
employed to determine 10B concentrations and microdosimetry in the intracranial nerves,
which are essential to the sensory systems such as sight and hearing.
(3) When the rate constants derived from a human PET glioblastoma study[3] are
used in conjunction with blood data from mice to predict the normal brain tissue 10B
concentrations in mice, the experimental normal brain data fit very well with the
prediction. This suggests that human and mouse have similar BPA-f metabolism and
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pharmacokinetics in normal brain tissues, and supports the applicability of the three-
compartment model and associated rate constants.
One implication from conclusion number 3 is that 10B is transported into the
normal brain in the form of BPA. In the mouse normal brain, only the amount of 10B in
the tissues is measured, while in the PET study, it is the 18F that is detected. Neither
measurement can independently provide any information on the chemical form of the
substance being measured. However, since both 10B and 18F are covalently bound to the
phenylalanine ring, it is very likely that they are both transported into the normal brain
tissue as the BPA parent. Due to the similar chemical structures of the two, the rate
constants are also very similar. This leads to the accurate prediction of mouse normal
brain 10B concentrations by the rate constants obtained from '8F-BPA PET study.
From the experiments with the GL261 murine glioma tumor and the B16
intracranial melanoma, it is shown that tumor 10B biodistribution exhibits a different
pattern for different tumor lines. The observations are as follows:
(1) GL261 tumor cells take up BPA-f very rapidly, with the 10B concentration of
GL261 cells being approximately 7 times of the 10B concentration in normal brain just 30
minutes after bolus injection. However, the 10B concentration in GL261 cells also
decreases rapidly, so that by 240 minutes after injection, it is only approximately 2 times
the 10B concentration in normal brain. Both the tumor to normal brain ratio and the
tumor to blood ratio vary in time.
For GL261 glioma tumor, the optimal time for neutron irradiation may be
approximately 60 minutes after the bolus injection, a relatively narrow window. During
this time, both the tumor to normal brain and tumor to blood ratio are similar, and are
about 6. Since it is not known whether the source of BNCT-induced injury to normal
brain is due to vascular or parenchymal damage, this time, 60 minutes, represents the
most conservative approach.
(2) The B16 cells also takes up BPA-f rapidly, with the tumor 10B concentration
reaching approximately 8 - 10 times that of the normal brain tissue at 30 minutes after
injection. However, the '0B concentration decreases much more slowly in the B 16 cells.
By 240 minutes after injection, B 16 cells still possess 5 - 6 times 10B concentration than
in the normal brain.
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Since the tumor 10B concentration decreases less rapidly in B16 tumors, the
neutron irradiation could be performed during the time frame between shortly before 60
minutes to approximately 70 or 80 minutes after the bolus injection. Since the 10B
concentrations of brain tissue and of blood cross over between 80 to 100 minutes after
injection, the tumor to normal tissue and the tumor to blood 10B concentration ratio will
change in the opposite directions during the time frame between 60 - 80 minutes. The
actual target tissue for normal brain radiation damages will determine which time point is
better suited for neutron irradiation, this issue is clearly demonstrated in figure 4.1.
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(3) For GL261 tumors, the rate constants k1 through k4 obtained from three-
compartment pharmacokinetic model are 0.14 ml/g/min, 0.12 min-, 0.08 min', and 0.036
min-i, respectively.
(4) For B16 intracranial melanoma, the values k1 through k4 are 0.22 ml/g/min,
0.19 min-, 0.058 min-, and 0.01 lmin1 .
The rate constants of both tumor models differ substantially from the values
Imahori obtained for GBM, which are 0.027 ml/g/min, 0.041 min', 0.029 min-land 0.013
min-, respectively. As mentioned in section 3.3.3, the most notable differences between
the GL261 and the B 16 are the initial influx across the blood-brain-barrier, and the efflux
from the intracellular compartment. A plausible hypothesis is as follows: BPA-f is an
analogue of a melanin precursor and B 16 cells have more transport carriers on their cell
membranes, therefore contributing to the higher influx rate initially. However, it is
conceivable that once the precursors get into the cells, they become associated with but
not assimilated into melanin as suggested by Mishima[4]. Therefore, the efflux from the
intracellular compartment decreases for B16 cells.
From the B16 intracranial melanoma study, two additional conclusions can be
made:
(5) intracranial melanoma has higher 10B concentrations than subcutaneous
melanoma. This may due to the difference in vascular supply to the tumors.
(6) For all time points studied, the subcutaneous melanoma B concentration is at
least approximately 2 times that of skin, while at 30 minutes after injection, the
subcutaneous melanoma is about 3 times of the 10B concentration in skin.
These studies show that for different tumor cell lines, there are differences in
BPA-f pharmacokinetics and that the same cell line grown in different sites can also
exhibit different kinetics. The rate constants derived from the pharmacokinetic
compartmental vary widely, which could affect the timing of the irradiation. While
animal tumor models might not be accurate in predicting the pharmacokinetics of human
tumors, they can provide insightful information regarding the pharmacokinetics and
perhaps the transport mechanism of BPA-f, thus providing ideas for transport
manipulation. In addition, animal models are amenable to further experimentation with
irradiation at various times after BPA infusion. Clearly, however, the best way to
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determine the optimal irradiation time for human subjects is to study BPA-f
pharmacokinetics in humans.
The last experiment was concerned with the 10B biodistribution in hepatic
colorectal metastases. Several observations have been made:
(1) Due to the hypovascular nature of hepatic colorectal metastases, the boron
accumulation in the tumor lagged behind that of the normal liver, but quickly rose and
surpassed that of the normal liver. By 15 min after the bolus injection the metastases had
1.5 times the boron concentration in blood, increasing to approximately 2.5 times by 60
min after injection, and decreasing again to about 1.5 times at 240 min. Similar trends
were observed for tumor/normal liver, and tumor/skin. Tumor boron was approximately
1.3 times that in normal liver at 15 min, 1.8 times at 30 min, 2 times at 60 min and 120
min, and barely 1 at 240 min after the bolus injection.
(2) The skin 10B concentrations are consistently higher than blood and normal
liver (except for the earliest time point), approximately 1.7 times of liver. Therefore, it
may be the primary target organ for determining limiting toxicity. Dose profiles for skin
and hepatic colorectal metastases obtained using the FCB and the medium head phantom
appear to confirm this, although accurate RBE values for the skin, liver and hepatic
colorectal metastases could change the dose profiles obtained.
While the 10B concentration ratio is lower than that seen in experimental brain
tumor models, this is an encouraging result considering the constraints of the host
environment, liver, which is a highly vascularized organ. However, with the high skin
10B concentrations, to obtain a therapeutic ratio of greater than unity in liver represents a
challenge for BNCT. Additional research should be conducted to derive the RBEs for the
liver and the hepatic colorectal metastases. Once obtained, it will be possible to generate
detailed dosimetric calculations and to determine the suitability of BNCT for the
treatment of hepatic colorectal metastasis.
4..2 Recommendations for Future Work
From these experiments, a number of possibilities for future work have emerged.
First, there might be experiments that could be conducted to resolve the question of the
radiation damage target for BNCT. Currently, there are conflicting theories, although
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some experiments have shown that vascular damage is probably the cause for necrosis in
rat spinal cord, thereby suggesting that the vascular endothelial cells are the target cells
rather than the CNS parenchyma[5]. From the pharmacokinetic results shown in this
work, two sets of irradiation experiments can be done to distinguish between these two
potential targets. For the first experiment, the irradiation would be administered shortly
after the BPA-f injection, approximately 5 - 10 minutes. During this period, the
blood/normal brain B concentration ratio is very high, therefore, it CNS necrosis is
observed, it could be concluded that the vascular endothelial cells are the primary target
of BNCT radiation damage. For the second experiments, the animals would be irradiated
200 - 250 minutes after BPA-f injection. During this period, the normal brain 10B
concentration is approximately 2 - 4 times higher than the blood. If necrosis is observed,
it would suggest that the CNS parenchyma is the primary target.
There are other experiments that can be conducted which would shed some light
on the transport mechanism of BPA-f into tissues. First, there is the issue of spatial 10B
biodistribution in different brain structures. Amino acid studies have yielded data that
suggest that there is differential influx for different amino acids in various brain
structures[2]. Current experimental results also suggest that there is an elevated uptake of
0B in the cerebellum and the intracranial nerves. Three types of experiments can be
conducted to further investigate this issue. The first is to conduct similar animal studies
using a large animal model with higher spatial resolution, such as dogs, to determine
the10B concentrations in these two structures. Secondly, the 10B concentrations in these
structures can be quantified using a microscopic technique, such as HRQAR. HRQAR
can not only quantify 10B in minute tissue samples, thus resolving the problem of
inadequate spatial resolution in a small animal model, it can also be used to study the
microdistribution of BPA-f in these brain structures, thus furthering our understanding of
the dosimetry in these tissues. Thirdly, an experiment can be conducted in which a tracer
quantity of 14C labeled amino acid is infused and blood samples measured for amino acid
concentrations, including competing amino acids. The samples could be thinly sectioned
for quantitative autoradiography. By adequately taking into account the effects of protein
incorporation and dilution to free amino acid pool, influx rates can be calculated[2]. The
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principle of this approach is basically similar to that of the present research, but done at a
higher spatial resolution.
Other research possibilities include manipulation of BPA-f influx using
competing amino acids. The goal of such research would be to increase the amount of
BPA-f transported into the tumor cells, thus elevating the 10B concentration and further
increasing the therapeutic ratio. Both phenylalanine and tyrosine are large neutral amino
acids (LNAA) and are mainly transported into cells by the L-system. It has been shown
in cell culture that BPA uptake is predominantly by the Na+-independent L-system, and
that BPA efflux from cells is also dependent on the L-system[5]. It has also been shown
that the phenylalanine influx can be affected by the concentrations of other LNAA. By
preloading the cells with tyrosine, the influx will increase, but if the system receives an
infusion of leucine, the plasma concentration of tyrosine and phenylalanine are decreased
by 40% and 45% respectively[6]. Once the transport mechanism of BPA-f is known, it
will be possible to utilize the data gathered from the amino acid/protein metabolism
research to manipulate the transport system in such as way as to increase BPA-f uptake.
These experiments should first be conducted in cell culture, and then in small animal
models such as the those used in this research. The new data, along with that presented
in this research, can contribute to a more comprehensive pharmacokinetic model, in
which the rate constants can be predicted based on the infusion scheme and the
manipulations applied.
In addition to manipulating the amino acid concentrations in the system to
preferentially increase BPA-f influx, another possibility is to increase the 10B
concentration in the blood. Neutral amino acids such as phenylalanine distribute readily
into erythrocytes due to the presence of specific neutral amino acid transport systems on
the red cell plasma membrane. Therefore, the blood cell amino acid red pool is
important. The literature has suggested that once phenylalanine is absorbed by red blood
cells, it is no longer available to be transported through the blood-brain barrier in vivo [7].
It has also been shown that human red blood cells have a specific amino transport system,
the T-system[8], which is not present in most other cells. The T-system is a Na+-
independent system that shows significant transport of the aromatic amino acids
tryptophan, tyrosine, and phenylalanine[8]. Since BPA-f is derived from phenylalanine,
90
but structurally similar to tyrosine, it is possible that BPA-f is also taken up into red
blood cells by the T-system. Since the L-phenylalanine uptake by erythrocytes is
saturable and nonconcentrative[9], it is conceivable that if the T-system in the red blood
cells can be blocked, the concentration of phenylalanine and tyrosine in plasma will be
elevated.
Better compartment models can also be derived if the transport mechanism and
biochemical metabolism of BPA-f is understood. Numerous data are available on amino
acid metabolism and protein turnover, which can provide useful data for modeling when
the nature of BPA-f metabolism is known.
With respect to the issue of timing of the irradiation following BPA infusion, the
present research shows that for different tumor cell lines, there may be a different optimal
time frame. Therefore, more research should be focused on determining the
pharmaokinetics of individual tumors by in vivo techniques, such as PET[3] and MRI.
However, better resolution is a requirement for such an endeavor. From well
vascularized animal tumors, it can be seen that the tumor uptake might be much higher
than that observed in biopsies with necrotic regions. The study on the relationship
between 1B concentration and cellularity[1] also supports this observation. Therefore,
better resolution than PET or MRI data will be needed to better predict the optimal
irradiation time frame.
Finally, more animal studies could be conducted with the hepatic colorectal
metastasis model to find the RBEs for liver, tumor, skin, and other gastrointestinal organs
in the irradiation field. Dosimetic calculations could be done to further investigate the
suitability of BNCT for this specific tumor. In addition, if this tumor shows some
preferential uptake in a very challenging host environment, it is conceivable that other
tumor types might also prove to have preferential BPA-f uptake compared to surrounding
tissue. This possibility is well worth investigating.
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